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Chapter 1: Introduction  
8 
1.1 Epidemiology of prostate cancer 
Prostate cancer (PCa) is the most common cancer in men in Europe and the US [1, 2]. 
According to the most recent data approximately 1 in 7 US men will develop PCa 
during his lifetime [3]. In the Netherlands in 2011, 11,428 men were diagnosed with 
PCa and 2,500 men died as a result of the disease [4]. The incidence of PCa generally 
increases with advancing age [5, 6]. It is relatively rare for PCa to be diagnosed in men 
before age 50, but after this age, incidence rates increase exponentially [7]. A 
worldwide increase in PCa incidence is expected as the male population ages [5]. 
The incidence of PCa is strongly influenced by early detection with the use of the 
serum prostate-speciﬁc antigen (PSA) test, one of the most commonly used clinical 
cancer tests [8, 9]. In 1994, the US Food and Drug Administration (FDA) approved the 
use of the PSA test in conjunction with a digital rectal exam to test asymptomatic men 
for PCa [8, 10]. PSA testing has now become common practice in many developed 
countries. Based on results of the Statistics Netherlands survey, in 2012, 24.4% of men 
older than age 39 in the Netherlands had their serum PSA measured in the previous 5 
years [11]. This percentage was highest for men aged 65 to 75 years (44.4%) and 75 or 
older (40.9%).  
PCa is a clinically heterogeneous disease with marked variability in patient 
outcomes [5, 12]. While many PCa patients will have slow-growing, indolent tumors 
that may never become clinically-relevant other patients will have aggressive disease 
associated with metastasis and death from PCa [13]. The frequent occurrence of 
indolent or latent PCa is confirmed by several autopsy studies that showed that many 
men who die from other causes than PCa have evidence of histological PCa 
(approximately 30–50% of men aged 50–70 years) [7, 14, 15]. Since both PSA testing 
and latent PCa are common there is substantial overdiagnosis of PCa [16, 17]. It has 
been estimated that PCa overdiagnosis may occur in up to 67% of all cases [18]. 
Overdiagnosis of PCa is an important public health problem because it may lead to 
overtreatment. A consequence of PCa overtreatment is that many patients needlessly 
suffer from serious treatment-induced side effects (e.g., incontinence, impotence) 
[16].  
Advanced PCa is a type of PCa associated with a poor prognosis that is therefore 
clinically relevant [19]. The TNM system is a widely accepted cancer staging system 
that is used to identify advanced PCa [20]. The TNM system is based on the size or 
extent of the primary tumor (T), the amount of spread to nearby lymph nodes (N), and 
the presence of metastasis (M) [3]. Advanced PCa typically involves those tumors that 
either extend beyond the prostate (T3−4), show positive lymph node involvement 
(N1), or are metastatic (M1) [19, 20]. These cancers are classified by the International 
Union Against Cancer (UICC) as stage III and IV PCa [20]. Data from the Netherlands 
Cancer Registry (2003−2009) showed that while stage I/II prostate cancers have a 5-
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year survival rate of nearly 100%, this is much lower for advanced cancers, in particular 
stage IV prostate cancers (45%) [21]. Another prognostic marker of PCa is the Gleason 
Grading System, which is a predictor of PCa aggressiveness [22]. Gleason grade is 
based on cellular content and tissue architecture from biopsies and radical 
prostatectomy specimens and is typically used to identify aggressive rather than 
advanced PCa [22, 23]. 
Besides older age, other major risk factors for PCa are race and family history of 
PCa [5, 6, 24]. Incidence rates for men of African ancestry are nearly twice the 
incidence rates of their European and Asian counterparts [3]. PCa has shown to be one 
of the most hereditary cancers; the risk of developing the disease doubles for men 
with a ﬁrst-degree relative affected by PCa and increases further with more affected 
relatives [25]. Evidence from twin studies indicates that heritable factors may explain 
as much as 42% of PCa risk [26, 27]. No other established PCa risk factors have been 
identified and the causes of the disease remain poorly understood [5, 24, 28]. There is 
however increasing scientific evidence suggesting that the antioxidant nutrient 
selenium and the related oxidative stress pathway have a role in PCa [24, 29-31]. 
1.2 Selenium and selenoproteins 
The trace mineral selenium is an essential micronutrient of fundamental importance to 
human biology [32, 33]. The main dietary sources of selenium include ﬁsh, shellﬁsh, 
cereals, meat, and dairy products [34]. In contrast to many other micronutrients, the 
intake of selenium varies hugely worldwide [32, 33]. This variability in intake results 
from differences in selenium content of the soil on which crops are grown, and also 
differences in availability and chemical species of selenium in the soil [32]. 
Recommendations for selenium intake average 60 μg per day for men and 53 μg per 
day for women [33]. Selenium intakes are high in Venezuela, Canada, the US, and 
Japan. Europe is generally considered to have relatively low intakes [32]. China has 
areas of both selenium deﬁciency and excess [33]. Although the average selenium 
intake in the US is high, low selenium status may be common in certain US regions 
[35]. 
Selenium exerts biological functions through its presence in selenoproteins [36]. 
The human genome contains 25 selenoprotein genes. Selenoproteins are selenium-
dependent and the element is incorporated in these proteins as the (the 21st) amino 
acid selenocysteine [37]. Selenocysteine is encoded by the UGA codon, which is 
normally a stop codon [36]. Selenoprotein synthesis is an evolutionary conserved 
process that depends on multiple protein and RNA factors such as the selenocysteine 
insertion sequence (SECIS), SECIS-binding protein 2 (SBP2), and selenocysteine-tRNA 
[36, 38]. Although many selenoproteins have yet unknown functions, a number of 
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biological activities of selenoproteins have been described. These functions include the 
reduction of thioredoxins (thioredoxin reductase), selenophosphate synthesis 
(selenophosphate synthetase), and activation and inactivation of thyroid hormones 
(iodothyronine deodinase) [36, 38]. Selenium, however, is best-known for its 
antioxidant activities that are achieved through incorporation in the selenoenzyme 
family of glutathione peroxidases (GPXs) [36, 39, 40]. GPX decomposes reactive oxygen 
species (ROS) that can cause oxidative stress and associated damage when levels 
become too high [39]. Another well-characterized selenoprotein is selenoprotein P 
(SEPP1), a secreted glycoprotein that contains most of the selenium in plasma and is 
the main transport protein for selenium [41].  
1.3 Oxidative stress and antioxidants 
Reactive oxygen species, oxidative stress, and disease 
Reactive oxygen species (ROS) are oxygen radicals and non-radicals that are produced 
as byproducts of normal cellular metabolism [42-44]. A free radical is any species 
capable of independent existence that contains one or more unpaired electrons [43]. 
Examples of oxygen free radicals are the superoxide radical (O2
•−
) and the hydroxyl 
radical (OH
•
). Major non-radical derivatives of oxygen include hydrogen peroxide 
(H2O2) and singlet oxygen (
1
O2). An important endogenous source of ROS is the 
mitochondrial electron transport chain [45]. Other endogenous factors that generate 
reactive species include inflammatory processes, nitric oxide synthases (NOS), and lipid 
peroxidation [44]. ROS are also produced by exposure to exogenous pro-oxidants such 
as radiation, metal ions, cigarette smoke, ethanol, and some drugs [44]. While 
moderate concentrations of ROS are important for normal cellular functioning (e.g., 
cellular signaling), elevated concentrations of ROS are damaging and trigger a 
condition called oxidative stress [42-44]. This condition is associated with excessive 
oxidative damage to different cellular constituents (e.g., proteins, lipids, nucleic acids). 
Oxidative stress has been implicated in aging [46, 47], and is believed to play a role in 
age-related degenerative diseases including PCa [24, 30, 42, 48, 49]. Figure 1.1 
presents a scheme of the endo- and exogenous sources of ROS, associated cellular 
responses, and the potential link with PCa. 
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Figure 1.1 
Endo- and exogenous sources of reactive oxygen species, associated cellular responses, and the potential 
link with prostate cancer 
Abbreviations: reactive oxygen species, ROS; catalase, CAT; glutathione peroxidase, GPX; superoxide 
dismutase, SOD; nitric oxidase synthase, NOS 
Antioxidant enzymes and nutrients 
The burden of increased ROS production is counteracted by an intricate antioxidant 
defense system [42-44, 50]. Antioxidants are molecules that detoxify oxygen radicals 
and other ROS and thereby protect against oxidative stress. The antioxidant system 
includes both enzymes and dietary nutrients (Figure 1.1) [44, 50]. 
Key antioxidant enzymes are glutathione peroxidase (GPX), catalase (CAT), and 
superoxide dismutase (SOD) [44, 50]. GPXs are selenoproteins that have selenium as 
selenocysteine at their active site [39]. These enzymes catalyze the reduction of H2O2 
and other hydroperoxides using glutathione (Figure 1.2) [39]. There are 5 known 
selenium-dependent GPXs in humans, i.e. GPX1–4 and GPX6 [39]. Although their 
expression is ubiquitous, the levels of each isoform vary depending on the tissue type 
[50]. Catalase (CAT) is an enzyme present in the cell’s peroxisome where large 
amounts of ROS are produced [44, 50]. Like GPX, CAT also reacts with H2O2, which it 
reduces to water and oxygen (Figure 1.2). CAT has one of the highest turnover rates of 
all enzymes; one molecule of CAT can convert about 6 million molecules of H2O2 per 
minute [44]. SOD catalyzes the dismutation of O2
•−
 to oxygen and to the less-reactive 
H2O2 (Figure 1.2) [44, 50]. SOD exists in several isoforms that differ in the nature of the 
active metal center. In humans there are three forms of SOD, i.e.: cytosolic Cu, Zn-SOD 
H2O2 O2
•−
ROS
OH•
Less ROS More ROS
Redox homeostasisDisturbed 
cellular 
processes
Oxidative stress
Prostate cancer
Pro-oxidants
Endogenous
Mitochondria and peroxisomes
Enzymes (e.g., NOS)
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Diet (e.g., heme iron)
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(SOD1); mitochondrial Mn-SOD (SOD2); and extracellular SOD (SOD3). Because SODs 
generate H2O2, they have to work together with GPXs and CAT to remove H2O2 [43]. 
Besides these major antioxidant enzymes, there are a number of other enzymes with 
potentially important antioxidant activities (e.g., NADPH-quinone oxidoreductase, 
paraoxonase) [50, 51]. 
 
Figure 1.2 
Chemical reactions of the main antioxidant enzymes glutathione peroxidase, catalase, and superoxide 
dismutase 
Major antioxidant nutrients include vitamins C and E, carotenoids (e.g., β-
carotene and lycopene), flavonoids (e.g., catechins and flavonols), and selenium [44, 
52]. Vitamin C (ascorbic acid) works as an antioxidant in aqueous environments. It acts 
both directly by reaction with ROS and indirectly by restoring the antioxidant 
properties of vitamin E [44]. Vitamin E is a fat-soluble vitamin that inhibits ROS-
induced generation of lipid peroxyl radicals, thereby protecting against lipid 
peroxidation [52]. Vitamin E exists in eight different forms and α-tocopherol is the 
most active form in humans [44]. Approximately 600 different carotenoids have been 
described. The antioxidant properties of carotenoids are associated with their radical 
scavenging properties and their ability to quench 
1
O2 [53]. Flavonoids are another large 
family of naturally occurring compounds, with more than 5,000 members having been 
described. The antioxidant capacity of flavonoids is due to their ability to reduce free 
radical formation and to scavenge free radicals [44, 54]. The antioxidant activities of 
selenium are mainly attributed to the antioxidant enzymes GPX, which are selenium-
dependent [44]. 
1.4 Selenium, other antioxidants, pro-oxidants, and prostate cancer risk 
There have been a number of epidemiological studies that investigated the link 
between pro- and antioxidants and PCa risk. These investigations focused on both 
exogenous (external) and endogenous (internal) factors. Exogenous factors include 
Glutathione peroxidase (GPX) 
H2O2 + 2GSH → GSSG + 2H2O 
Catalase (CAT) 
H2O2 → 2H2O + O2 
Superoxide dismutase (SOD) 
2O2
•− + 2H+ → H2O2 + O2 
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various antioxidant nutrients including selenium, carotenoids, and vitamins; but also 
pro-oxidants exposures like smoking and dietary factors [42, 44, 55]. The studies on 
endogenous pro- and antioxidants focused on genetic variants. Variation in genes 
encoding pro- and antioxidant enzymes may influence oxidative stress levels and 
cellular responses [56]. 
Selenium 
Selenium has long been thought to have anticarcinogenic properties [31, 57, 58], and a 
chemopreventive effect of selenium has been demonstrated in a large randomized 
study: the Nutritional Prevention of Cancer (NPC) trial [59]. This study recruited 1,312 
volunteers with a previous history of non-melanoma skin cancer from the 
southeastern US, a region with low selenium soil concentrations. Participants were 
randomized from 1983 to 1991. The study showed that treatment with 200 μg 
selenium per day (as selenium yeast) had no effect on the primary outcome of non-
melanoma skin cancer, but in a secondary analysis the study found that selenium 
supplementation reduced the risk of total cancer (25%) and PCa (52%) [29, 60, 61]. 
Furthermore, the association between selenium levels and PCa risk has been studied in 
a number of prospective analyses. These observational studies generally support an 
association between higher selenium levels and lower PCa risk [29]. 
The effect of selenium supplementation on PCa incidence was further 
investigated in the Selenium and Vitamin E Cancer Prevention Trial (SELECT) [62]. 
SELECT is a phase 3 randomized, placebo-controlled trial that included 35,533 
American men. Participants were randomized from 2001 to 2004. The study showed 
that selenium supplementation (as selenomethionine; 200 µg/day) did not reduce PCa 
risk [62, 63]. The null result for selenium in SELECT was surprising given the substantial 
scientific evidence from earlier studies suggesting that selenium reduces PCa risk [29, 
60]. A number of possible explanations for these disparate findings have been 
proposed, in particular that baseline selenium levels in SELECT may have been too high 
for additional selenium intake to have a beneficial effect [33, 64-66]. Compared to the 
NPC trial, which was conducted among subjects from regions in the US with low 
selenium soil concentrations [59], SELECT included American men with relatively high 
baseline selenium (median plasma selenium level = 136 µg/L) [62]. This hypothesis is 
further strengthened by the observation that in the NPC trial selenium 
supplementation only reduced PCa risk among subjects in the two lowest tertiles of 
baseline selenium (<123 µg/L plasma selenium) [60]. Other possible explanations for 
the mixed results on selenium and PCa risk include differences in selenium species (in 
foods and supplements) and genetic variation in selenoprotein genes and related 
pathways [33, 64-66]. 
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Other antioxidant nutrients and pro-oxidant exposures 
Besides selenium other antioxidant nutrients have been investigated in relation to PCa 
risk. The Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study was 
designed to study the effect of vitamin E (as α-tocopherol) and β-carotene 
supplementation on the risk of lung cancer (primary endpoint) and other cancers 
(secondary endpoint) [67]. The trial included 29,133 male smokers from Finland and 
randomization took place from 1985 to 1988. The study showed that supplementation 
with vitamin E and β-carotene did not reduce lung cancer risk, but found that vitamin E 
supplementation lowered PCa risk [67, 68]. The preventive effect on PCa risk was, 
however, not significant after additional follow-up of the study population [69]. SELECT 
not only studied selenium but also vitamin E and, surprisingly, the trial showed that 
supplementation with vitamin E (as α-tocopherol) significantly increased PCa risk [63]. 
A number of prospective and case−control studies investigated antioxidant nutrients 
(intake or levels) in relation to PCa risk. These studies generally do not support an 
association with the nutrients investigated including vitamins C and E, β-carotene, and 
lycopene [55, 70]. A number of observational studies examined the associations 
between PCa risk and pro-oxidant exposures such as smoking [71], alcohol [72], and 
dietary iron [73, 74], but these studies generally do not support an association. 
Genetic variation in oxidative stress-related genes 
Genetic variation in genes encoding antioxidant enzymes and other oxidative stress-
related proteins may influence oxidative stress levels and responses. A number of 
previous candidate gene association studies investigated the associations between 
oxidative stress-related gene variants and PCa risk. These studies focused on single 
nucleotide polymorphism (SNPs), which represent differences in single nucleotides and 
are the most common type of genetic variation in humans [75]. When SNPs occur 
within a gene or in a regulatory region near a gene, they may play a role in disease by 
affecting the gene’s function. The previous studies on oxidative stress-related genetic 
variation and PCa risk showed significant associations with variants in several 
candidate genes such as SOD2, NOS2A, PON1, and hOGG1 [76-79]. These findings 
require confirmation from other studies because most associations were only reported 
in one or two small studies. Furthermore, most previous studies only investigated total 
PCa but not advanced PCa. 
The antioxidant system is a dynamic and redundant system that involves many 
endo- and exogenous components that protect against ROS produced by various in- 
and external sources [42-44]. It is, therefore, reasonable to assume that pro- and 
antioxidant genes and exposures do not merely act independently, but also have 
combined effects via gene−environment interactions. Studies of gene−environment 
interactions aim to describe how genetic and environmental factors jointly influence 
 
 
15 
disease risk [80, 81]. Relatively few epidemiological studies searched for interactions 
between oxidative stress-related gene variants and exposures on PCa risk. These 
studies showed some significant findings including interactions between SOD2 and 
selenium [82], and hOGG1 and α-tocopherol [79]. These findings require confirmation 
from other studies. 
1.5 Aims of the thesis 
The overall aim of the research described in this thesis was to investigate the link 
between selenium, selenoproteins, oxidative stress, and advanced PCa risk. In the first 
part of the thesis we examined how selenium status and selenoprotein genes impact 
PCa risk. The hypotheses were that low toenail selenium levels are inversely associated 
with advanced PCa risk, and selenoprotein gene variants modify advanced PCa risk and 
the selenium−PCa association. In the second part of the thesis we examined how 
various pro- and antioxidant genes and exposures impact PCa risk. We hypothesized 
that pro- and antioxidant exposures, oxidative stress-related gene variants, and 
gene−environment interactions between these two factors modify (advanced) PCa risk. 
1.6 Netherlands Cohort Study design 
The different analyses in this thesis were conducted within the prospective 
Netherlands Cohort Study [83]. The Netherlands Cohort Study included 58,279 men 
and 62,573 women, aged 55 to 69 years at baseline in September 1986. Netherlands 
Cohort Study participants completed a detailed baseline questionnaire on many 
potential cancer risk factors and provided toenail clippings, which were used to 
determine selenium concentrations and to isolate DNA for genotyping. Cancer cases 
were prospectively identified by annual record linkage to the Netherlands Cancer 
Registry and the Dutch Pathology Registry [84]. Clinical and pathological data from 
these registries were used to identify advanced PCa cases from all PCa cases. For the 
research in this thesis, a follow-up of 17.3 years was used. The thesis specifically 
focuses on advanced PCa, which is clinically relevant because it has a poor prognosis 
[19]. We used the UICC TNM system to classify PCa [20]. Two definitions of advanced 
PCa were used in our analyses: (1) UICC stage III/IV PCa, which is T3−4, N+, or M1 (i.e., 
T3N0M0; T4N0M0; T[any]N+M0; T[any]N[any]M1); and (2) UICC stage IV PCa, which is 
T4, N+, or M1 (i.e., T4N0M0; T[any]N+M0; T[any]N[any]M1). In our analyses, both 
definitions of advanced PCa were used. TNM information was available for the 
majority of cases in our study (94%). 
  
16 
The case−cohort design 
The Netherlands Cohort Study employs a case−cohort design [85]. This type of nested 
design involves selecting a single subcohort from the initial cohort at inception (n = 
2,411 male Netherlands Cohort Study participants), and adding all the cases that occur 
in the cohort (outside the subcohort). The subcohort is used to estimate the person-
time experience [85]. The advantage of this design is that it considerably reduces data 
collection, which is important because for our research we used costly and time-
consuming methods for exposure monitoring and genotyping [86]. The case−cohort 
design is similar to the nested case−control design, which however can be inefficient 
when a cohort study is used to investigate multiple outcomes as is the case in the 
Netherlands Cohort Study. 
Selection of single nucleotide polymorphisms, DNA isolation, and genotyping 
For the research described in this thesis we utilized a candidate gene association 
approach. This approach involves analyzing single nucleotide polymorphisms (SNPs), 
which represent the most common type of genetic variation in humans [75]. We 
studied SNPs in candidate genes encoding major selenoproteins (SEPP1, GPX1) and 
other oxidative stress-related proteins (e.g., CAT, SOD2, hOGG1, NOS2A). Two 
different SNP selection strategies were used in this thesis; i.e., selecting (1) tagging 
SNPs to capture all common variation in genes (selenoprotein genes) and, (2) 
candidate SNPs that have reported functionality or have been associated with PCa risk 
in previous studies (oxidative stress-related genes). SNP genotyping was done using 
DNA isolated from toenail clippings of study participants. Our group previously showed 
that stored toenail samples of Netherlands Cohort Study participants are a stable and 
very useful source of DNA for SNP genotyping [87]. Genotyping was done using 
Sequenom’s MassARRAY® technology (Sequenom, Hamburg, Germany). 
1.7 Outline of the thesis 
In Chapter 2 of this thesis we studied the association between toenail selenium levels 
and advanced PCa risk. In Chapter 3 we investigated whether SEPP1 and GPX1 genetic 
variants were associated with advanced PCa risk and modified the association between 
toenail selenium levels and advanced PCa risk. In Chapter 4 and 5 we examined the 
associations between major pro- and antioxidant exposures and advanced PCa risk. In 
Chapter 6 we investigated the associations between oxidative stress-related genetic 
variants and advanced PCa risk and the gene−environment interactions with pro- and 
antioxidant exposures. Finally, Chapter 7 provides a general discussion of the thesis.   
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Abstract 
Background 
Selenium may prevent advanced prostate cancer (PCa), but most studies on this topic 
were conducted in populations with moderate to high selenium status. We 
investigated the association of toenail selenium, reflecting long-term selenium 
exposure, and advanced PCa risk in a population from the Netherlands where low 
selenium status is widespread. 
Methods 
The analysis was conducted in the prospective Netherlands Cohort study, which 
included 58,279 men aged 55 to 69 years at baseline in 1986. All cohort members 
completed a baseline questionnaire and 79% of participants provided toenail clippings, 
which were used for toenail selenium measurements using instrumental neutron 
activation analysis. Incident advanced PCa cases from the entire cohort were identified 
during 17.3 years of follow-up. The study employed a case−cohort design for which a 
random subcohort was sampled at baseline. Hazard ratios (HRs) and 95% confidence 
intervals (CIs) were estimated using Cox proportional hazards regression models. All 
tests were two-sided. 
Results 
Complete toenail selenium data were available for 898 advanced (UICC stage III/IV) 
PCa cases and 1,176 subcohort members. The average toenail selenium concentration 
of subcohort members was 0.550 µg/g. Toenail selenium was associated with a 
reduced risk of advanced PCa; adjusted HR for the highest versus lowest quintile was 
0.37 (95% CI: 0.27, 0.51; P for trend <0.001). For stage IV PCa, men in the highest 
versus lowest quintile of toenail selenium had an adjusted HR of 0.30 (95% CI: 0.21, 
0.45; P for trend <0.001). 
Conclusion 
Toenail selenium was associated with a substantial decrease in risk of advanced PCa. 
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Introduction 
Selenium is an essential micronutrient that is incorporated into proteins as part of the 
amino acid selenocysteine and exerts important biological functions through its 
presence in these selenoproteins [1, 2]. The intake of selenium varies hugely 
worldwide as a result of global variations in the selenium soil content and related 
variability in the selenium content of foods [3, 4]. While the average selenium intake is 
high in the US, low selenium intake is estimated to be widespread in Europe [3, 4]. 
Selenium-containing supplements also add to these intakes, especially in the US where 
dietary supplements are commonly used [4]. Within the US, however, selenium intake 
may vary substantially and low selenium status may be common in certain US regions 
[5]. 
The association of selenium and PCa has been studied in a number of prospective 
studies with some analyses showing an inverse association, particularly for advanced 
PCa, and others showing no relationship [6]. Interestingly, the association has been 
mainly studied over a relatively narrow range of selenium with levels from moderate 
to high. Most studies were conducted in populations from the US that did not include 
men with low selenium status who are at higher risk of less-overt selenium-deficiency 
[3, 6]. Most studies of selenium and PCa risk used blood for exposure monitoring, but 
selenium concentrations can also be measured in toenails [6]. While blood selenium 
reflects recent exposures in the order of weeks, toenail selenium reflects exposures 
that have occurred over six months to one year and is, therefore, ideal for monitoring 
long-term exposure [6, 7]. Three prospective studies of toenail selenium and PCa risk 
have been conducted and one of these studies is a previous analysis in the Netherlands 
Cohort Study, which had a follow-up for incident PCa of 6.3 years [8]. The analysis 
showed an association with a reduced risk of overall PCa and a statistically non-
significant association with a reduced risk of advanced PCa. The study included only 
183 advanced PCa cases and, therefore, had limited power to study the relationship. 
Also, due to the limited follow-up time in the study, the potential effect of long-term 
follow-up on the association could not be examined. The two other prospective studies 
of toenail selenium and PCa also had a small number of cases and a limited follow-up 
[6].  
Despite the evidence from large prospective studies of an inverse association 
between selenium and PCa [6], such a relationship is not supported by the Selenium 
and Vitamin E Cancer Prevention Trial (SELECT) [9, 10]. The clinical trial among 
American men showed no association of selenium supplementation and PCa incidence 
after a median follow-up of seven years [10]. One possible explanation for the null 
result is the high median baseline selenium level of men in SELECT (136 μg/L) [4, 11, 
12]. In an earlier clinical trial, it has been shown that selenium supplementation to 
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men with blood selenium concentrations of more than 122 μg/L does not reduce the 
risk of cancer and in fact may even increase cancer risk [4, 13, 14]. 
We investigated toenail selenium levels of participants in the Netherlands Cohort 
Study. The study was conducted over a wide range of selenium that included low 
selenium. After a follow-up of 17.3 years, the analysis included 898 advanced PCa 
cases. The aim of the analysis was to investigate whether higher toenail selenium 
levels are associated with a decreased risk of advanced PCa.   
Methods 
Study population 
The Netherlands Cohort Study included 58,279 men, aged 55 to 69 years at baseline in 
September 1986. All cohort members completed a baseline questionnaire and 79% of 
participants provided toenail clippings from all toes, which were used for selenium 
measurements [15]. Cancer cases were identified by annual record linkage to the 
Netherlands Cancer Registry and the Dutch Pathology Registry [16, 17]. The 
Netherlands Cohort Study has a case−cohort design; case subjects are derived from the 
entire cohort and the person-time experience is estimated from a subcohort randomly 
sampled from the full cohort at baseline (n = 1,688) [18]. In our analysis, we excluded 
all cases with prevalent cancer other than skin cancer at baseline and men with 
incomplete or inconsistent dietary questionnaire data [19, 20]. The Netherlands Cohort 
Study has been approved by the institutional review boards of the TNO Nutrition and 
Food Research Institute and Maastricht University. 
 
Ascertainment and classification of prostate cancer cases 
During 17.3 years of follow-up, 3,451 incident PCa cases were identified. In the present 
analysis, we evaluated advanced PCa only (International Union Against Cancer (UICC) 
[21] stage III/IV), which was defined as T3−4, N+, or M1 at diagnosis (n = 1,196). Stage 
IV (UICC) PCa is a subset of advanced PCa and was defined as stage T4, N+, or M1 at 
diagnosis (n = 753). A number of cases had missing data on tumor stage (n = 216). 
Baseline characteristics (e.g. age, smoking, and PCa family history) were not different 
between cases with and without data on tumor stage. 
Exposure assessment 
Selenium concentrations were measured in toenail clippings by the Reactor Institute 
Delft, using instrumental neutron activation analysis of the 
77m
Se isotope. Each sample 
went through six cycles of 17-second irradiation at a thermal neutron flux of 3 x 10
16
 
m
-2
s
-1
, 3-second decay, and 17-second counting at 1 cm from a 40% germanium 
detector. The accuracy of the analysis was checked by a certified bovine liver standard 
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(Standard Reference Material 1577b of the US National Institute of Standards and 
Technology). This method and the Netherlands Cohort Study toenail selenium project 
have been described in more detail previously [22-24].  
Toenail selenium measurements for the subcohort were carried out in 1992. In 
2002, toenail selenium levels of advanced PCa cases diagnosed during the first 6.3 
years of follow-up were determined [8]. In 2011, toenail selenium levels of advanced 
PCa cases diagnosed during 6.3 to 17.3 years of follow-up were measured. In 1992, the 
‘Snelle Buizen Post’ (SBP) facility was used for instrumental neutron activation analysis, 
and, since 1996, the ‘Carbonfiber Autonomous Facility for Irradiation and Analysis’ 
(CAFIA) facility is used. To assess the validity and comparability of these two methods, 
toenail selenium levels of the same 40 subcohort members were determined in 1996 
with the ‘CAFIA’ facility in addition to the original assessment with the ‘SBP’ facility 
[25]. The mean selenium level (µg/g) assessed by the ‘CAFIA’ facility (0.552; standard 
deviation (SD): 0.05) was similar to the mean selenium level (µg/g) assessed by the 
‘SBP’ facility (0.551; SD: 0.04), with a Pearson correlation coefficient of 0.95 (P <0.01) 
[25]. It was concluded that both methods were valid and comparable. 
Available toenail material from all toes was used for the selenium determination. 
We excluded participants who did not provide a toenail sample or had a sample with a 
too low sample weight (<10 mg). Baseline characteristics (e.g. age, smoking, and PCa 
family history) were not different between men with and without toenail selenium 
data. Complete toenail selenium data were available for 898 advanced PCa cases and 
1,176 subcohort members. 
Statistical analysis 
We compared average toenail selenium levels of cases diagnosed in different years of 
follow-up to evaluate to potential influence of prediagnostic cancer at baseline on 
toenail selenium levels. Cox proportional hazards regression was used to obtain hazard 
ratios (HRs) and 95% confidence intervals (CIs) for the association between quintiles of 
toenail selenium and advanced PCa risk. Standard errors were estimated by using the 
robust Huber-White sandwich estimator, to account for additional variance introduced 
by sampling from the cohort [18, 26]. Cut-off points for each quintile were based on 
the distribution of toenail selenium in the subcohort. P-values for linear trends were 
calculated by using median values within toenail selenium quintiles. For the continuous 
analysis we used an increment of 0.045 µg/g of toenail selenium, which is the width of 
the central quintile. We completed age-adjusted and multivariable models adjusted for 
age, first-degree family history of PCa, smoking status, duration of smoking, and 
frequency of smoking. We adjusted for cigarette smoking because it has been shown 
to be an important predictor of toenail selenium status [5, 23]. The proportional 
hazards assumption was tested using the scaled Schoenfeld residuals [27], and we 
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found no violation of the assumption. Time on study (follow-up) was used as time 
scale. Results were unchanged when age instead of time on study was used as time 
scale. 
Several other variables were considered as potential confounders including: non-
occupational physical activity, education level, body mass index, history of diabetes, 
long-term use of non-steroidal anti-inflammatory drugs, black tea consumption, and 
intake of energy, alcohol, calcium, catechin, lycopene, red meat, and vitamin E. None 
of these was included in the final models, as they had little effect on the effect 
estimates or precision. We studied whether the association of toenail selenium and 
advanced PCa risk differed according to follow-up time by stratifying the follow-up 
time into two periods: <8 and ≥8 years. Effect modification of the association between 
quantiles of toenail selenium and advanced PCa risk by other covariables was tested by 
using cross-product terms in the regression models and by examining stratum-specific 
HR-estimates. The Wald statistic was used to test for interaction. The following 
variables were considered as potential effect modifiers: first-degree family history of 
PCa, smoking status, body mass index, black tea consumption, and dietary antioxidant 
score. The antioxidant score is a measure of combined intake of β-carotene, catechin, 
lycopene, vitamin C, and vitamin E (sum of quartile scores that range from 0 (low 
intake) to 3 (high intake)) and it has been described in more detail previously [28]. All 
tests were two-sided, with a P-value of less than 0.05 considered to be statistically 
significant. Analyses were performed using STATA software (release 12).  
Results 
Cases and subcohort members had an average toenail selenium level (µg/g) of 0.527 
and 0.550, respectively. We evaluated mean toenail selenium levels of cases diagnosed 
in different years of follow-up and we found no trend towards lower or higher levels 
indicating that there was no effect of preclinical disease (Table 2.1). Compared with 
subcohort members, cases were more likely to have a first-degree relative affected 
with PCa and less likely to have a history of diabetes (Table 2.2).  
Toenail selenium was associated with a decreased risk of advanced (stage III/IV) 
PCa. Adjusted HRs (95% CIs) for increasing quintiles of toenail selenium were 1.00 
(reference), 0.75 (0.57, 1.00), 0.59 (0.44, 0.79), 0.43 (0.31, 0.58), and 0.37 (0.27, 0.51) 
(P for trend <0.001) (Table 3). The association was slightly more pronounced for stage 
IV PCa with an adjusted HR for the highest versus lowest quintile of toenail selenium of 
0.30 (95% CI: 0.21, 0.45) (Table 2.3).  
Table 2.4 shows the association between quintiles of toenail selenium and risk of 
advanced PCa stratified by period of follow-up. Adjusted HRs (95% CIs) of advanced 
PCa (highest versus lowest quintile) for <8 and ≥8 years of follow-up were 0.47 (0.30, 
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0.76) and 0.31 (0.21, 0.45), respectively. The different outcome was also observed for 
stage IV PCa. The average age at diagnosis (SD) for advanced PCa cases who were 
diagnosed <8 and ≥8 years of follow-up was 68.5 (4.2) and 74.5 years (4.7), 
respectively. The percentage of first-degree family history of PCa was higher for men 
who were diagnosed <8 years of follow-up (5.3%) compared to ≥8 years of follow up 
(2.8%). Other characteristics were not different for these case groups. 
There was no statistically significant interaction for any of the covariables tested 
for advanced PCa (Table 2.5). However, the association of tertiles of toenail selenium 
with advanced PCa appeared less pronounced for men with a first-degree family 
history of PCa (P for interaction = 0.504). Furthermore, in stratified analysis, toenail 
selenium was associated with a reduced risk of advanced PCa among former smokers 
and current smokers, but not among never smokers (P for interaction = 0.306). 
Table 2.1 
Mean toenail selenium level (µg/g) and standard deviation of men with advanced prostate cancer, per year 
of follow-up, Netherlands Cohort Study, 1986-2003a 
      Toenail selenium level (µg/g) 
Casesb No. cases Mean SD 
All cases 898 0.527 0.169 
Year of follow-up    
 1 21 0.524 0.060 
 2 17 0.530 0.077 
 3 23 0.531 0.106 
 4 35 0.538 0.090 
 5 36 0.505 0.094 
 6 55 0.542 0.090 
 7 57 0.508 0.092 
 8 76 0.555 0.428c 
 9 68 0.526 0.150 
 10 77 0.511 0.065 
 11 77 0.553 0.238 
 12 65 0.523 0.082 
 13 54 0.539 0.146 
 14 54 0.517 0.078 
 15 56 0.538 0.122 
 16 56 0.524 0.097 
 17 56 0.500 0.070 
  18 15 0.471 0.053 
Abbreviation: SD, standard deviation. 
a Advanced (stage III/IV) prostate cancers were stage T3−4, N+, or M1 at diagnosis. 
b Mean toenail selenium level (SD) of subcohort members was 0.550 µg/g (0.129). 
c The large SD is the result of an extreme, but biologically plausible, observation (4.174 µg/g). 
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Table 2.2 
Characteristics of advanced prostate cancer cases and subcohort members, Netherlands Cohort Study, 
1986−2003 
    Advanced prostate 
cancer casesa  
Subcohort members  
  (n = 898)  (n = 1,176)  
Variables % Mean (SD) % Mean (SD) 
Age at baseline, years   62.1 (4.1)   61.3 (4.2) 
Age at diagnosis, years  72.3 (5.3)  − 
First-degree family history of prostate cancer 3.7  2.6  
Smoking status       
 Never 13.9  13.8  
 Former 56.1  53.3  
 Current 30.0  32.9  
Duration of smoking†, years  32.5 (12.2)  32.8 (12.0) 
Frequency of smoking, cigarettes/dayb  16.1 (10.4)  16.9 (10.5) 
High (>90 minutes/day) non-occupational 
physical activity 
33.5  31.9  
Higher vocational or university education 21.3  18.0  
Body mass index, kg/m2  25.0 (2.5)  25.0 (2.7) 
History of diabetes 2.2  3.3  
Long-term use of NSAIDsc 5.0  6.5  
Black tea consumption, cups/day  2.6 (2.0)  2.6 (2.0) 
Dietary intake     
 Energy, kcal/day  2,157 (480)  2,160 (505) 
 Alcohol, g/day  14.5 (15.5)  14.5 (16.7) 
 Calcium, g/day  956 (322)  942 (332) 
 Catechin, mg/day  58.2 (38.0)  57.8 (37.0) 
 Lycopene, mg/day  1.1 (1.6)  1.0 (1.6) 
 Red meat, g/day  91.9 (39.6)  93.0 (41.6) 
 Vitamin E, mg/day  15.2 (6.7)  14.8 (6.7) 
 β-carotene, mg/day  2.9 (1.4)  3.0 (1.6) 
 Vitamin C, mg/day  101.2 (41.9)  98.8 (40.9) 
Abbreviations: SD, standard deviation; NSAIDs, non-steroidal anti-inflammatory drugs. 
The variable ‘Age at diagnosis’ does not apply to subcohort members. 
a Advanced (stage III/IV) prostate cancers were stage T3−4, N+, or M1 at diagnosis. 
b Never smokers were excluded. 
c Use of aspirin or other NSAIDs for a period of at least six months. 
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Discussion 
This prospective long-term follow-up study in the Netherlands showed that toenail 
selenium was associated with a decreased risk of advanced PCa, with men in the 
highest compared to the lowest quintile of toenail selenium having a 63% reduced risk. 
Strengths of our study include the prospective design, population-based 
approach, long and nearly complete follow-up of the study population through linkage 
to cancer registries, and detailed data on potential confounders. We specifically 
evaluated advanced PCa and our study included a large number of these cases. Our 
study was conducted over a wide range of selenium that included low selenium. We 
used toenail selenium for exposure monitoring, which reflects long-term selenium 
intake. The study has some limitations as well. Selenium levels of study participants 
were determined at different points in time and this may have introduced bias. To 
avoid bias by analyzing stored toenail samples at different time points, the same 
standard reference material was used to check the accuracy of the neutron activation 
analyses over time. Another limitation is that we only measured selenium at baseline 
and had no repeated exposure measurements. 
There have been three previous prospective analyses of toenail selenium and PCa 
risk. One of these studies was an earlier analysis in the Netherlands Cohort study [8]. 
The analysis included cases who were diagnosed during 6.3 years of follow-up and the 
relative risks of overall and advanced PCa were assessed (540 PCa cases; 183 advanced 
cases). The study showed that men in the highest versus lowest quintile of toenail 
selenium had a decreased risk of overall PCa (HR = 0.69; 95% CI: 0.48, 0.99) and 
advanced PCa (HR = 0.62; 95% CI: 0.37, 1.05). An US-based study by Helzlsouer et al. 
(117 cases and 233 controls) showed an HR of overall PCa of 0.38 (95% CI: 0.17, 0.85) 
for men in the highest versus lowest quintile of toenail selenium [29]. Advanced PCa 
risk was not assessed in that study. Mean toenail selenium was higher in the study by 
Helzlsouer et al. compared to the Netherlands Cohort Study (quintile medians (µg/g) 
ranging from 0.66−0.96 and 0.43−0.67, respectively). In another US-based study of 
toenail selenium, Yoshizawa et al. specifically evaluated advanced PCa [30]. The study 
included 181 advanced PCa cases and 181 controls and toenail selenium quintile 
medians ranged from 0.66−1.14 µg/g. The authors reported an adjusted odds ratio of 
0.35 (95% CI: 0.16, 0.78) for men in the highest compared to the lowest quintile of 
toenail selenium. 
Most observational studies of selenium and PCa have used plasma/serum rather 
than toenails for exposure monitoring [6]. Data of these studies have been pooled in a 
recent meta-analysis that evaluated both overall PCa (nine studies) and advanced PCa 
(six studies) [6]. For overall PCa, the authors found a gradual reduction in risk over the 
plasma/serum selenium range investigated (60−170 μg/L), with an estimated relative 
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risk (95% CI) at 135 and 170 μg/L of 0.85 (0.74, 0.97) and 0.75 (0.65, 0.86), 
respectively. The association was more pronounced for advanced PCa (same range of 
selenium) with an estimated relative risk (95% CI) at 135 and 170 μg/L of 0.60 (0.45, 
0.81) and 0.50 (0.36, 0.68), respectively. Most of the pooled studies were conducted in 
the US where selenium intake is often high. 
Our results further support that selenium intake may be an important modifiable 
factor that reduces the risk of advanced PCa. We specifically evaluated advanced PCa, 
because these cancers have a poor prognosis and are, therefore, clinically relevant. 
Several studies have provided evidence that the relationship between selenium and 
cancer may be U-shaped, with a higher risk associated with levels both below and 
above an optimal selenium range [4, 31]. The Nutritional Prevention of Cancer (NPC) 
trial showed that selenium supplementation was associated with a reduced risk of 
total PCa risk. The association, however, was only present among participants with 
baseline plasma selenium concentrations in the lowest two tertiles; those in the 
highest tertile (>122 µg/L) showed a non-significant increase in risk [13, 14]. In our 
study, quintile medians of toenail selenium ranged from 0.43 to 0.67 µg/g. This range 
of toenail selenium was estimated to be equivalent to (quintile medians) 64−100 µg/L 
plasma selenium by using the method described by Waters et al. [31]. These estimated 
levels are comparable to observed plasma selenium levels reported in other 
epidemiological studies in the Netherlands [32-35]. Based on results of the NPC trial, 
selenium levels in our study are in the range where additional selenium is expected to 
be beneficial, in the proposed U-shaped curve [4, 31]. In addition, we observed that 
the association of toenail selenium and advanced PCa risk was slightly more 
pronounced for men diagnosed during later follow-up at an older age. Prostate cancer 
diagnosed at a younger age is more often related with a positive family history of PCa, 
and it may be that selenium is less effective for preventing this type of PCa, which may 
be fundamentally different from sporadic PCa [36, 37]. Most prior prospective studies 
of selenium and PCa had a follow-up time that was considerably shorter than in our 
study and did not include results for separate follow-up periods. Further large and 
long-term follow-up studies are therefore urgently needed. 
Most of our study participants were smokers (either former or current), with only 
14% of men having never smoked. A number of studies showed evidence that the 
inverse association of selenium and PCa risk is particularly evident among smokers [8, 
38-40]. This finding is biologically plausible given that selenium is an antioxidant and 
smoking results in increased oxidative stress [2]. In a stratified analysis, we showed 
that toenail selenium was inversely associated with advanced PCa risk among smokers, 
but not among never smokers, with no significant interaction. The analysis included 
only 125 cases who were never smokers, suggesting that power may have been too 
low. 
34 
Prospective studies showing evidence of an association between selenium and 
reduced PCa risk are not supported by SELECT [10]. A number of possible explanations 
for these different findings have been suggested. In particular, it may be that baseline 
selenium levels in SELECT were too high to have an effect of further selenium 
supplementation on PCa risk [4, 11, 12]. The interquartile range of baseline serum 
selenium in SELECT was 122−152 μg/L and prior evidence showed that subjects in this 
range of baseline selenium have no benefit from selenium supplementation [4, 13, 14]. 
It would, therefore, be of great interest to see SELECT results stratified by baseline 
selenium levels. Several observational studies showed a greater effect of selenium on 
advanced versus non-advanced PCa. Because of prostate-specific antigen (PSA) 
screening practices in the US, in SELECT, PCa was most often diagnosed at localized 
stages; only 1% of men diagnosed with PCa in SELECT had stage T3 at diagnosis [10]. In 
comparison, in the Netherlands Cohort Study, where PSA screening is less frequent, 
35% of incident PCa was advanced PCa. 
In conclusion, our large prospective analysis showed that higher toenail selenium 
concentrations were associated with a substantial decrease in risk of advanced PCa. If 
our results are confirmed, a prevention trial of selenium and PCa in a low-selenium 
population may be justified.  
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Abstract 
Background 
Lower selenium levels have been associated with increased risk of prostate cancer 
(PCa), and genetic variation in the selenoprotein genes selenoprotein P (SEPP1) and 
glutathione peroxidase 1 (GPX1) is thought to modify this relationship.  
Methods 
We investigated whether the association between toenail selenium levels and 
advanced PCa risk in the prospective Netherlands Cohort Study is modified by common 
genetic variation in SEPP1 and GPX1. Toenail clippings were used to determine 
selenium levels and to isolate DNA for genotyping. This case−cohort study, including 
817 advanced PCa cases and 1048 subcohort members, was analyzed with Cox 
regression models. All statistical tests were two-sided.  
Results 
Three genetic variants were associated with advanced (stage III/IV or IV) PCa risk: 
SEPP1 rs7579 (P for trend = 0.012), GPX1 rs17650792 (P for trend = 0.033), and GPX1 
rs1800668 (P for trend = 0.005). Toenail selenium levels were inversely associated with 
advanced PCa risk, independently of common genetic variation in SEPP1 and GPX1. 
Conclusion 
Common genetic variants in SEPP1 and GPX1 were marginally associated with 
advanced PCa risk but did not modify the association between toenail selenium levels 
and advanced PCa risk. 
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Introduction 
The micronutrient selenium is a key component of selenoproteins that have important 
biological activities [1]. Lower selenium levels have repeatedly been associated with an 
increased PCa risk [2-4]. However, some large epidemiological studies [2], including the 
Selenium and Vitamin E Cancer Prevention Trial (SELECT) [5], do not support this 
inverse relationship. As a result of these disparate findings, it has been hypothesized 
that the effect of selenium on PCa is modified by selenoprotein gene variation [3, 6-8]. 
Plausible candidate selenoprotein genes to genetically modify the selenium-PCa 
association are selenoprotein P (SEPP1) and glutathione peroxidase 1 (GPX1). Genetic 
variants in both genes have previously been identified as having an effect on PCa risk 
[7, 9]. Furthermore, these genes have known essential biological functions; SEPP1 is 
involved in selenium transport [10], and GPX1 counteracts oxidative stress [11]. 
We investigated common SEPP1 and GPX1 variation in relation to advanced PCa 
risk and examined potential interactions with selenium levels measured in toenail 
samples. In a previous report, based on the same study population, we showed that 
men in the highest versus lowest toenail selenium quintile had a more than 60 percent 
reduced risk of advanced PCa [12]. 
Methods 
Study population and design 
The Netherlands Cohort Study included 58,279 men, aged 55 to 69 years at baseline in 
1986 [13]. Approximately 81% of participants provided toenail clippings, which were 
used to determine selenium levels and to extract DNA. Cancer cases were identified 
during 17.3 years of follow-up by annual record linkage to cancer registries [14]. 
Advanced PCa was defined as T3−4, N+, or M1 at diagnosis (International Union 
Against Cancer stage III/IV [15]) (n = 1290). Stage IV PCa was defined as stage T4, N+, 
or M1 at diagnosis (n = 817). The study had a case-cohort design and a flow diagram of 
study participants is shown in Figure 3.1. The study was approved by the institutional 
review boards of TNO and Maastricht University. Study participants gave informed 
consent. 
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Figure 3.1 
Flow diagram of cases and subcohort members for the analysis of genetic variants in selenoprotein P and 
glutathione peroxidase 1, toenail selenium levels, and advanced prostate cancer risk, Netherlands Cohort 
Study, 1986−2003 
Abbreviations: NCR, Netherlands Cancer Registry; PALGA, Dutch Pathology Registry. 
a Advanced prostate cancer was defined as T3−4, N+, or M1 at diagnosis (International Union Against Cancer 
stage III/IV). On average, 63% of stage III/IV prostate cancer cases were stage IV prostate cancer (stage T4, 
N+, or M1 at diagnosis).  
b Analysis 1 was on SEPP1 and GPX1 genetic variation in relation to advanced prostate cancer risk and 
included 952 stage III/IV prostate cancer cases and 1,798 subcohort members. Samples with a sample call 
rate (i.e., percentage of called SNPs per sample) of less than 95% were excluded. 
c Analysis 2 was on potential interactions between SEPP1 and GPX1 genetic variants and toenail selenium 
levels on advanced prostate cancer risk and included 817 stage III/IV prostate cancer cases and 1048 
subcohort members. A smaller version of the subcohort (70%) was used for this analysis. 
Selection of genetic variants and genotyping 
Tagging single nucleotide polymorphisms (tagSNPs) were identified utilizing the 
HapMap CEU population and parameters of r
2
 ≥0.8 and minor allele frequency ≥10% 
[16]. SNPs were selected within genes and 5000 base pairs upstream and downstream. 
We identified five tagSNPs in SEPP1 and three in GPX1. DNA was extracted from 
toenails as described previously [17]. DNA was successfully isolated for 1,030 cases and 
1,885 subcohort members (>99.9% successful DNA isolation). Genotyping was done 
using MassARRAY software (v4.0) and the iPLEX Gold system (Sequenom Inc., 
Hamburg, Germany). Quality control included genotyping of blind duplicate samples, 
which revealed >99% agreement on genotyping calls. Samples with a sample call rate 
of less than 95% were excluded and a total of 952 cases and 1,798 subcohort members 
had complete genotyping data. Most SNPs had >99% genotype completion rates with 
the exception of rs230819 (85.7%). None of the SNPs violated Hardy-Weinberg 
equilibrium (P >0.05). 
Selenium concentrations 
Selenium concentrations were measured in toenails using instrumental neutron 
activation analysis [12]. For the gene−environment interaction analysis, we used a 
smaller subset of the subcohort (70%) [18]; 817 cases and 1,048 subcohort members 
had complete genotyping and toenail selenium data. 
Statistical analyses 
Age-adjusted Cox proportional hazards regression models were used. The proportional 
hazards assumption was tested using the scaled Schoenfeld residuals [19], and we 
found no violation of the assumption. SNPs were analyzed under a co-dominant and 
log-additive genetic model. Standard errors were estimated using the robust Huber-
White sandwich estimator [20, 21]. Multiplicative interactions of quartiles of toenail 
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selenium and genotype (dominant model) were tested using cross-product terms and 
the Wald test. Selenium quartiles were based on the distribution in the subcohort. 
Interaction models were adjusted for age, first-degree family history of PCa, smoking 
status, and duration and frequency of smoking, as described previously [12]. Several 
other potential confounders were considered [12], but none of these were selected as 
they had little effect on the effect estimates (<5%) or precision. All statistical tests 
were two-sided, with P-value <0.05 considered to be statistically significant. Analyses 
were performed using STATA software (Release 12, STATA Corporation, College 
Station, TX). 
Results 
Two GPX1 SNPs were associated with advanced (stage III/IV) PCa risk (Table 3.1). For 
GPX1 rs17650792, hazard ratios (HRs) for AA, AG, and GG were 1.00 (reference), 1.14 
(95% confidence interval (CI) = 0.95, 1.37), and 1.29 (95% CI = 1.01, 1.63); P for trend = 
0.033. For GPX1 rs1800668, HRs for CC, CT, and TT were 1.00 (reference), 0.81 (95% CI 
= 0.68, 0.96), and 0.73 (95% CI = 0.54, 0.97); P for trend = 0.005. The HRs were similar 
for stage IV PCa. SEPP1 SNPs were not associated with stage III/IV PCa risk, but SEPP1 
rs7579 was associated with stage IV PCa risk, with HRs for GG, AG, and AA of 1.00 
(reference), 0.81 (95% CI = 0.66, 0.99), and 0.71 (95% CI = 0.51, 1.00); P for trend = 
0.012.  
Higher toenail selenium levels were associated with a reduced risk of advanced 
PCa in all genotype subgroups (Table 3.2). None of the tested multiplicative 
interactions between genotype and selenium status were statistically significant. 
Results were comparable for stage IV PCa. When using only one reference category 
(i.e., men in the lowest selenium quartile with the common homozygote genotype), we 
observed evidence of a genetic effect of SEPP1 rs3877899, SEPP1 rs7579, and GPX1 
rs3448 on advanced PCa risk among men in the lowest quartile of toenail selenium 
(Table 3.3).  
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Discussion 
In this long-term prospective analysis of advanced PCa risk we observed no statistical 
interactions between toenail selenium levels and SEPP1 and GPX1 genetic variants. 
Studies investigating the effect of selenium on (advanced) PCa incidence have had 
mixed results [2, 4, 5, 12]. Our results indicate that it is unlikely that these disparate 
findings are the result of differences in SEPP1 and GPX1 variation. We showed that 
higher toenail selenium levels were associated with a decreased risk of advanced PCa 
in all genotype subgroups. 
We observed SEPP1 and GPX1 variant main effects on advanced (stage III/IV or 
IV) PCa risk. These are mostly novel findings [7, 9, 22]. GPX1 rs1800668 is in high 
linkage disequilibrium with rs1050450 (r
2
 = 0.9), which resides in the coding region, 
results in an amino acid substitution of proline with leucine [23, 24], and may, 
therefore, be the true functional polymorphism. 
Strengths of our study include the prospective design and large number of 
advanced, clinically relevant, PCa cases. We comprehensively investigated all common 
variation in SEPP1 and GPX1 using a tagging SNP approach. A limitation of our study is 
that we measured toenail selenium status once at baseline but had no repeated 
measurements during follow-up. 
In conclusion, our data showed that low-selenium is associated with an increased 
risk of advanced PCa, independently of common genetic variation in SEPP1 and GPX1. 
Specific SEPP1 and GPX1 variants may, however, have a main effect on advanced PCa 
risk. The null findings of prior studies of selenium and PCa may at least partially be 
explained by the possibility that additional selenium intake only benefits men with 
relatively low selenium levels and not those who are selenium replete [6, 7, 12].  
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Appendix 1: Haplotype analysis 
Linkage disequilibrium (LD) plots were constructed using Haploview to explore the LD 
structure of the data [1]. Haplotype blocks were assembled in Haploview using the 
method described by Gabriel et al. [2], and haplotype risk within each block was 
assessed. 
Figure A1.1 shows the LD plot for SEPP1. One haplotype block was identified and 
that block consisted of SEPP1 rs7579, which had an independent association with stage 
IV PCa risk (Table 3.1). There were five haplotypes in this block; four, which carried the 
G risk allele of SEPP1 rs7579. We found no evidence of an association with advanced 
PCa risk for any of the haplotypes (Table A1.1).  
Figure A1.2 shows the LD plot for GPX1. One haplotype block was identified and 
that block included all three SNPs. GPX1 rs17650792 and rs1800668 had an 
independent association with advanced PCa risk (Table 3.1). There were three 
haplotypes in this block; one, which carried the G risk allele of rs17650792 and the C 
risk allele of rs1800668. This haplotype was not associated with advanced PCa risk 
(Table A1.2). 
 
Figure A1.1 
Linkage disequilibrium across SEPP1 SNPs in subcohort members, Netherlands Cohort Study 
Darker shading indicates higher degrees of pairwise r2 correlation, such that r2 = 1 is shown as black and r2 = 
0 is shown as white. SNPs rs230813 and rs230819 were in moderate LD (r2 = 0.76). The numbers in squares 
represent pairwise D’ (first two decimal numbers shown), with blank boxes indicating D’ = 1. 
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Table A1.1 
Hazard ratio (HR) and 95% confidence interval (CI) for the association of SEPP1 haplotypes and risk of 
advanced prostate cancer, Netherlands Cohort Study, 1986−2003abc 
    Advanced (stage III/IV)  
prostate cancerd 
Stage IV prostate cancere  
  No. cases HR (95% CI) No. cases HR (95% CI) 
Two copies of 'GGGT' SEPP1 haplotype         
 No 759 1.00 462 1.00 
 Yes 193 1.00 (0.81, 1.22) 133 1.13 (0.89, 1.42) 
Two copies of 'CGAC' SEPP1 haplotype     
 No 926 1.00 578 1.00 
 Yes 26 1.30 (0.78, 2.16) 17 1.36 (0.76, 2.45) 
Two copies of 'CGAT' SEPP1 haplotype     
 No 946 1.00 591 1.00 
  Yes 6 0.95 (0.35, 2.58) 4 1.02 (0.32, 3.23) 
a All models were adjusted for age at baseline (years). 
b One of the haplotypes (CGGT) was not investigated because only 1 case carried two copies of the 
haplotype. 
c The G risk allele of rs7579, which was marginally associated with advanced prostate cancer risk in our 
study, is highlighted in bold. 
d Advanced (stage III/IV) prostate cancers were stage T3−4, N+, or M1 at diagnosis. 
e Stage IV prostate cancers were stage T4, N+, or M1 at diagnosis. 
 
Figure A1.2 
Linkage disequilibrium across GPX1 SNPs in subcohort members, Netherlands Cohort Study 
Darker shading indicates higher degrees of pairwise r2 correlation, such that r2 = 1 is shown as black and r2 = 
0 is shown as white. All pairwise D’ were 1. 
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Table A1.2 
Hazard ratio (HR) and 95% confidence interval (CI) for the association of GPX1 haplotypes and risk of 
advanced prostate cancer, Netherlands Cohort Study, 1986-2003ab 
    Advanced (stage III/IV)  
prostate cancerc 
Stage IV prostate cancerd  
  No. cases HR (95% CI) No. cases HR (95% CI) 
Two copies of 'GGC' GPX1 haplotype         
 No 770 1.00 483 1.00 
  Yes 182 1.20 (0.97, 1.48) 112 1.18 (0.92, 1.50) 
a All models were adjusted for age at baseline (years). 
b The G risk allele of rs17650792 and the G risk allele of rs1800688, which were both marginally associated 
with advanced prostate cancer risk in our study, are highlighted in bold. 
c Advanced (stage III/IV) prostate cancers were stage T3−4, N+, or M1 at diagnosis. 
d Stage IV prostate cancers were stage T4, N+, or M1 at diagnosis. 
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Abstract 
Background 
Oxidative stress is possibly related to prostate carcinogenesis. We constructed a 
dietary antioxidant score, which is a measure of combined antioxidant intake, and an 
oxidative balance score, which is a measure of combined pro- and antioxidant intake. 
We hypothesized that both scores are inversely associated with prostate cancer (PCa) 
risk.  
Methods 
We conducted a case−cohort study among 58,279 men in the Netherlands Cohort 
Study. Cohort members completed a baseline questionnaire. From 1986 to 2003, 3,451 
PCa patients were identified including 1,196 advanced cancers (stage III or IV). The 
antioxidant score and the oxidative balance score were created by summing quartile 
and category scores of individual score constituents, which had an equal weight. Pro-
oxidants were scored in the opposite way to antioxidants.  
Results 
Both the antioxidant and oxidative balance score were not associated with risk of 
overall PCa or PCa subgroups based on disease stage. Most score constituents were 
not associated with PCa risk. Total catechin intake was associated with a decreased risk 
of stage IV PCa (HR for highest versus lowest quartile = 0.76; 95% CI: 0.59, 0.98).  
Conclusion 
We conclude that the antioxidant score and oxidative balance score were not 
associated with PCa risk. 
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Introduction 
Prostate cancer (PCa) is the most frequent cancer among males in developed countries 
[1]. Compared to other common cancers such as breast and lung cancer, little is known 
about risk factors for PCa [2-4]. 
A possibly important pathway in the age-related development and progression of 
PCa is the oxidative stress pathway [5-9]. Oxidative stress is an imbalance between the 
generation of reactive oxygen species (ROS) and antioxidant protection in favor of the 
former [10]. Intracellular levels of ROS are maintained by a complex network of 
antioxidant enzymes and metabolites [10, 11]. Many antioxidant metabolites are 
obtained from dietary sources. Examples of dietary antioxidants are vitamin C, vitamin 
E, selenium, and several carotenoids and flavonoids [11]. Human beings are also 
exposed to a whole range of dietary and non-dietary components that can directly or 
indirectly induce the production of ROS. Examples of such pro-oxidants are dietary 
iron, cigarette smoke, and alcohol [12-14].  
Observational studies of PCa indicated that selenium and lycopene have a 
probable preventive effect on PCa, but evidence for other antioxidants and pro-
oxidants is limited [4]. A number of human clinical trials were conducted to test the 
role of dietary antioxidants in the prevention of PCa and collective data from these 
trials indicate that antioxidant supplementation does not prevent PCa [6]. 
A number of observational studies described different antioxidant scores [15-18]. 
These scores were constructed by summing quantile scores of antioxidant nutrient 
intake or level, where individual nutrients were given an equal weight. A high score 
reflected a high overall antioxidant status. One nested case−control study investigated 
the association between antioxidant score (based on plasma levels) and PCa risk and 
showed that the score was inversely associated with risk of overall PCa and that this 
association was more pronounced for advanced PCa [16]. 
Some other studies used an oxidative balance score [19-23]. An oxidative balance 
score is constructed by summing quantile or category scores of both antioxidant and 
prooxidant intake or level where pro- and antioxidants are scored in the opposite way. 
One small population-based case−control study showed an inverse association 
between the oxidative balance score and PCa risk [20], but this was not confirmed by a 
more recent prospective cohort study [19]. 
The goal of our study was to further investigate the associations between 
antioxidant score, oxidative balance score, individual score constituents, and risk of 
PCa. This investigation was carried out within the framework of The Netherlands 
Cohort Study, a large prospective cohort study that included 58,279 men. We have 
data on numerous pro- and antioxidants. Since PCa risk factors may differ for 
58 
subgroups based on the pathologic manifestations of this disease [24], we additionally 
investigated risk of PCa subgroups based on disease stage. 
Methods 
Study population 
The Netherlands Cohort Study (NLCS) is an ongoing prospective cohort study that 
started in September 1986. The NLCS includes 58,279 men, aged 55 to 69 years at 
baseline. All cohort members completed a baseline questionnaire [25]. Follow-up for 
incident cancer has been established by record linkage to the Netherlands cancer 
registries and the pathology registry PALGA [26]. The completeness of cancer follow-up 
through linkage with these cancer registries was assessed to be at least 96% [27]. The 
NLCS uses a case−cohort approach for data processing and analysis; case subjects were 
derived from the entire cohort and the person-time experience was estimated from a 
subcohort randomly sampled from the full cohort at baseline [28]. 
The present study is based on a follow-up of 17.3 years (September 1986 to 
December 2003). In our analysis, we excluded all cases with prevalent cancer other 
than skin cancer at baseline and individuals with incomplete or inconsistent dietary 
data. Our study included 3,451 incident PCa cases and 2,191 subcohort members. 
The NLCS has been approved by the institutional review boards of the TNO 
Nutrition and Food Research Institute (Zeist, the Netherlands) and Maastricht 
University (Maastricht, the Netherlands).  
Classification of prostate cancer cases 
Because of the considerable heterogeneity in the nature of PCa, we evaluated PCa 
subgroups based on disease stage. Advanced prostate cancers (International Union 
Against cancer (UICC) [29] stage III or IV) included tumors with stage T3 or T4, N+, or 
M1 at diagnosis. Stage IV (UICC) prostate cancers are a subset of advanced prostate 
cancers and included tumors with stage T4, N+, or M1 at diagnosis. Prostate cancers 
that were not identified as advanced cancers were classified as non-advanced prostate 
cancers (UICC stage I or II; T1 or T2 and N0 and M0). Our study included 1,196 
advanced cancers and 2,039 non-advanced cancers. Of all advanced prostate cancers, 
753 were stage IV prostate cancers.  
Exposure assessment 
Dietary intakes of study participants were derived from a food frequency 
questionnaire (FFQ). This dietary assessment was part of a larger questionnaire that 
also included questions regarding lifestyle and health. The FFQ was shown to be valid 
and reliable and is described in greater detail elsewhere [25, 30, 31]. 
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Contents of β-carotene, lycopene, and catechins in foods and beverages were 
derived from food composition tables based on data gathered in the Netherlands [32-
34]. In our study, total catechin refers to (+)-catechin, (−)-epicatechin, (+)-
gallocatechin, (−)-epigallocatechin, (−)-epicatechin gallate, and (−)-epigallocatechin 
gallate.   
Antioxidant and oxidative balance score 
We constructed an antioxidant score and an oxidative balance score. The antioxidant 
score included intakes of vitamin C, β-carotene, lycopene, vitamin E, and total 
catechin. The oxidative balance score included these antioxidant intakes plus the 
variables heme iron intake, smoking status, and alcohol intake (all pro-oxidants). These 
antioxidant and prooxidant exposures were included in previously described 
antioxidant scores and oxidative balance scores [15-23]. 
All continuous score variables were divided into quartiles based on the 
distribution of these variables among male subcohort members. Men in the first, 
second, third, and fourth quartile of antioxidant intake were assigned zero, one, two, 
and three points respectively. Scoring for prooxidants was conducted in the opposite 
fashion. Smoking status was categorized as never (three points), former (1.5 points), or 
current (zero points). Alcohol consumption was categorized as abstainer (three points), 
0.1 to 4 g/day (2.25 points), 5 to 14 g/day, (1.5 points), 15 to 29 g/day (0.75 points), or 
≥30 g/day (zero points). The range of antioxidant score values and oxidative balance 
score values was 0−15 and 0−24, respectively.   
Data analysis 
We used Cox proportional hazards regression to obtain hazard ratios (HRs) and 
corresponding 95% confidence intervals (CIs). Cut-off points for each quartile were 
based on the distribution of each variable in the subcohort. Tests for linear trend were 
carried out by taking the median values of each quartile or category and modeling 
exposure as a continuous variable. All models were adjusted for age at baseline as a 
continuous variable. The following factors, which are hypothesized or known to be 
associated with the studied exposures or PCa risk, were assessed as potentially 
confounding variables: family history of PCa among first degree relatives (yes/no), 
duration of smoking (years), frequency of smoking (cigarettes/day), non-occupational 
physical activity (≤30, >30−60, >60−90, >90 minutes/day), BMI (<23, 23−<25, 25−<27, 
27−<30, ≥30), height (cm), diabetes (type I or II, yes/no), education level (primary 
school, lower vocational, high school, higher vocational/university), and intakes of 
energy (kcal/day) and calcium (g/day). We evaluated, using a backwards stepwise 
procedure, whether these variables changed the point estimates by at least 10%. 
Because none did so, our final model was adjusted for age at baseline only. The 
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proportional hazards assumption was tested using the scaled Schoenfeld residuals 
[35]. Standard errors were estimated by using the robust Huber-White sandwich 
estimator, to account for additional variance introduced by sampling from the cohort 
[36]. 
Overall antioxidant status might depend on exposure to toxic constituents 
present in cigarette smoke. Cigarette smoke is a hugely complex mixture of toxic 
agents that can directly or indirectly induce oxidative stress [13]. We therefore 
investigated if the antioxidant score was differently associated with PCa risk in 
subgroups based on smoking status (never, former, current). These models were 
additionally adjusted for duration of smoking (smoking years) and frequency of 
smoking (cigarettes/day). We tested for interactions by using cross-product terms in 
the regression model. 
All P-values were two-sided, with a P-value less than 0.05 considered to be 
statistically significant. Analyses were performed using STATA software (release 11, 
STATA Corporation, College Station, TX). 
 
Results 
The baseline characteristics of our study population are shown in Table 4.1. Compared 
with subcohort members, PCa cases were more likely to have a first degree relative 
affected with PCa and less likely to have a history of diabetes. Baseline characteristics 
of all other factors were comparable between cases and subcohort members. 
We present age-adjusted HRs and 95% CIs. The antioxidant score was not 
associated with overall, non-advanced (stage I or II), advanced (stage II or IV), or stage 
IV PCa risk (Table 4.2). Total catechin intake was associated with a decreased risk of 
stage IV PCa (HR for the highest versus lowest quartile = 0.76; 95% CI: 0.59, 0.98; P for 
trend = 0.019). No significant associations were observed for overall, non-advanced, or 
advanced PCa risk. Associations were not observed for the other single antioxidants. 
We investigated the association between the antioxidant score and PCa risk 
among subgroups based on smoking status. Among former smokers, the antioxidant 
score was associated with an increased risk of overall PCa (HR for the highest versus 
lowest quartile = 1.38; 95% CI: 1.09, 1.75; P for trend = 0.008) (Table 4.3). No 
significant associations were observed among never and current smokers. The 
antioxidant score was not associated with non-advanced or advanced PCa risk among 
men with a different smoking status. 
The oxidative balance score was not associated with a decreased risk of overall, 
non-advanced, advanced, or stage IV PCa risk (Table 4.4). The oxidative balance score 
was associated with a modest increased risk of non-advanced PCa (HR for highest 
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versus lowest quartile = 1.20; 95% CI: 1.00, 1.44; P for trend = 0.031). Smoking status 
and alcohol and heme iron intake were not associated with PCa risk. 
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Discussion 
We constructed an antioxidant score and an oxidative balance score and investigated 
associations between these scores and PCa risk. We found that both scores were not 
associated with risk of PCa or PCa subgroups based on disease stage.  
All constituents of our antioxidant score were used in previously described 
comparable scores [15-18]. Flavonoids such as catechins and flavonols are 
polyphenolic antioxidants [37]. Flavonoids were included in the antioxidant score 
described by Wright et al. [18]. We included total catechin intake in our score because 
this is the major flavonoid subclass in our population. Other flavonoids were not 
included because (intake of) these were highly correlated with total catechin intake. 
Our antioxidant score incorporates antioxidant nutrients that are derived from a 
variety of food sources. The best sources of vitamin E are vegetable oils and fats. Major 
sources of vitamin C, β-carotene, and lycopene are fruits and vegetables. The major 
source of catechins is black tea. 
One previous observational study investigated the association between 
antioxidant score and PCa risk [16]. This nested case−control study by Li et al. (496 
cases and 402 controls) showed an inverse association between the antioxidant score 
(highest versus lowest category) and risk of overall PCa (RR = 0.60; 95% CI: 0.39, 0.88) 
and aggressive PCa (RR = 0.40; 95% CI: 0.25, 0.69) but not non-aggressive PCa [16]. This 
antioxidant score was derived by summing quartile scores of selenium, α-tocopherol, 
and lycopene levels in blood. This score is in many ways different from our antioxidant 
score. One major difference is related to the selection of score constituents. Our score 
included more constituents than the score by Li et al. [16] but did not include selenium 
status. Selenium status was not included in our score because these data were not 
available for 17.3 years of follow-up. Our Netherlands Cohort Study previously showed, 
for 6.3 years of follow-up, that toenail selenium status was associated with a reduced 
risk of overall PCa (HR for highest versus lowest quintile = 0.69; 95% CI: 0.48, 0.99) 
[38]. Another major difference is that while we used data on nutrient intakes Li et al. 
used data on antioxidant blood levels [16]. Biomarker data may provide more biologic 
insight since biomarkers are integral measures of intake, absorption, and metabolism 
of nutrients [22]. 
Most of our individual antioxidant score constituents were not associated with a 
decreased risk of PCa. The only exception is total catechin intake, which was associated 
with a decreased risk of stage IV PCa. Few epidemiological studies investigated 
associations between catechin intake and PCa risk and the few that have reported null 
results [39, 40]. Our finding therefore requires confirmation. We unexpectedly 
observed that men in the highest compared to the lowest quartile of lycopene intake 
had a modest increased risk of stage IV PCa. Numerous other observational studies 
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showed an inverse association between lycopene intake and PCa risk [4]. Our result 
may therefore be due to chance. 
We investigated whether the association between the antioxidant score and PCa 
risk was different among men with a different smoking status. We hypothesized that 
male smokers compared to never and former smokers benefit more from a high 
overall antioxidant intake. Unexpectedly we observed that among former smokers, 
men in the highest compared to the lowest quartile of antioxidant score had an 
increased risk of overall PCa. No associations were observed in the group of never and 
current smokers. This finding warrants further study. 
Our oxidative balance score included the same variables as our antioxidant score 
plus the variables heme iron intake, smoking status, and alcohol intake. Smoking 
status, alcohol intake, and iron intake were included in previously described oxidative 
balance scores (19-23). We preferred heme iron over total iron because this is the 
most bio-available form of dietary iron and as such is the greatest contributor to 
physiologic iron stores [18, 23].  
One previous prospective study and case−control study investigated the 
association between oxidative balance score and PCa risk [19, 20]. A small case−control 
study by Goodman et al. (89 cases and 197 controls) showed a significant inverse 
association between oxidative balance score and PCa risk [20]. Odds ratios for the 
middle and highest categories of oxidative balance score (predominance of antioxidant 
exposures) compared to the lowest category (predominance of pro-oxidant exposures) 
were 0.29 (95% CI; 0.12, 0.71) and 0.28 (95% CI; 0.10, 0.82), respectively. A prospective 
cohort study by Agalliu et al. (661 prostate cancers of which 173 were advanced) 
observed no association between oxidative balance score and risk of overall PCa or PCa 
subgroups based on disease stage [19]. Constituents of our score were also included in 
the oxidative balance scores described by Goodman et al. and Agalliu et al. [19, 20]. 
These scores however included some additional dietary constituents such as specific 
carotenoids (α-carotene, β-cryptoxanthin, lutein, and zeaxanthin), polyunsaturated 
fatty acids, cruciferous vegetables, and red meat. These additional variables were not 
included in our score because they were highly correlated with our other score 
constituents. Agalliu et al. reported a maximum correlation coefficient of 0.4 between 
the constituents of their score [19]. In our study, much stronger correlations were 
observed between our original score variables and these additional score variables. 
Both Agalliu et al. and Goodman et al. also combined dietary and supplemental 
nutrient intakes [19, 20]. This was not the case in our study. In our study, overall 
supplemental intake was very low and information on exact supplemental intake was 
not available. Another difference with the oxidative balance score by Goodman et al. is 
that they included the variables non-steroidal anti-inflammatory drugs (NSAIDs) use 
and aspirin use [20]. The motivation for that was that these drugs might prevent the 
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production of ROS by inhibition of inflammatory processes. These variables were not 
included in our score because very few individuals in our study population reported 
regularly (at least 6 months) using aspirin or NSAIDs (3% of male subcohort members 
for both NSAIDs and aspirin use). Overall, our result is in line with the result of the 
prospective study by Agalliu et al. [19], which showed that oxidative balance score is 
not associated with the risk of overall PCa or PCa subgroups based on disease stage. 
All factors included in our scores were given an equal weight. It is however 
unlikely that all studied pro- and antioxidants are equally potent. Besides that, the 
antioxidant activity of a compound might depend on the biological activity of other 
antioxidants. It is known for example that vitamin C reacts with vitamin E radicals to 
regenerate vitamin E [11]. Furthermore, our scores were probably incomplete. Not all 
possible pro- and antioxidant factors were included. Several carotenoids and other 
antioxidant nutrients were not included because they were correlated with other 
antioxidants in our score. Wright et al. countered this problem by utilizing principal 
components analysis [18]. This technique reduces a large number of highly correlated 
variables to a smaller set of components that capture as much of the variability in the 
data as possible. We however decided to not apply this technique because it would 
limit the comparability of our study with other studies [21]. Besides that, there are a 
number of other factors that are potential important candidates to include in an 
antioxidant or oxidative balance score such as exposure to environmental pollutants, 
work related exposures, and physical activity [41, 42]. 
Strengths of this study include the prospective design and large number of cases. 
The Netherlands Cohort Study had almost complete ascertainment of PCa cases and 
subcohort members and we had data on many pro- and antioxidants. 
In conclusion, both the antioxidant score and oxidative balance score were not 
associated with risk of overall PCa or PCa subgroups based on disease stage.  
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Abstract 
Background 
Flavonoids are natural antioxidants found in various foods and a major dietary source 
is black tea. There is some experimental evidence that flavonoids may prevent 
prostate cancer (PCa).  
Methods 
We investigated the associations between flavonoid intake, black tea consumption, 
and PCa risk in the Netherlands Cohort study, which included 58,279 men that 
provided detailed baseline information on several cancer risk factors. From 1986 to 
2003, 3,362 prostate cancers were identified including 1,164 advanced (stage III and 
IV) cancers. Cox proportional hazards regression using the case−cohort approach was 
used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs).  
Results 
Intake of total catechin, epicatechin, kaempferol, and myricetin and consumption of 
black tea were associated with a decreased risk of stage III/IV or IV PCa. HRs of stage 
III/IV and IV PCa for the highest versus the lowest category of black tea consumption 
(≥5 versus ≤1 cups/day) were 0.75 (95% CI: 0.59, 0.97) and 0.67 (95% CI: 0.50, 0.91) 
respectively. No associations were observed for overall and non-advanced PCa.  
Conclusion 
In conclusion, dietary flavonoid intake and black tea consumption were associated 
with a decreased risk of advanced PCa.  
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Introduction 
Flavonoids are a large group of polyphenolic antioxidants that are found in various 
foods of plant origin [1, 2]. These compounds are classified into different subclasses 
and for the major subclasses of flavonols and catechins, comprehensive data on their 
content in foods are available [1]. Flavonoids are abundantly present in green tea and 
black tea, which are both produced from the leaves of the plant Camellia sinensis [3-5]. 
The key chemical differences between both tea types result from post-harvest 
processing. In the processing of green tea, fresh tea leaves are heat-treated 
immediately after harvest, resulting in minimal oxidation of the naturally occurring 
polyphenols. In the processing of black tea, tea leaves are dried and crushed upon 
harvesting to encourage oxidation, which converts part of the endogenous tea 
polyphenols (primarily catechins) to other polymeric polyphenols such as theaflavins 
and thearubigens [5]. Besides tea other foods contribute significantly to flavonoid 
intake and these include apples, onions, chocolate, legumes, cabbages, and leafy 
vegetables [3, 4]. 
Several lines of experimental evidence suggest that flavonoids have specific 
chemopreventive effects on PCa. Epigallocatechin-3-gallate (EGCG) is the most 
abundant green tea catechin and the most studied flavonoid and it has significant 
growth inhibitory properties in PCa cells [6]. A number of animal studies showed that 
both green tea extracts and black tea extracts have inhibitory effects on PCa growth [6-
8]. Most of these studies used polyphenolic fractions isolated from green tea or 
purified EGCG. The anticancer effects of flavonoids may be related to their antioxidant 
effects or other properties such as effects on enzyme activities, anti-inflammatory 
effects, and inhibition of angiogenesis [9-11]. 
There has been one small proof-of-principle clinical trial among 60 men with high-
grade prostate intra-epithelial neoplasia that investigated the chemopreventive effects 
of green tea catechins (GTCs) on PCa [12, 13]. High-grade prostate intra-epithelial 
neoplasia is a likely precursor of PCa [14]. In this double-blind, placebo-controlled 
study, participants received three (200 mg) GTCs capsules per day. After 1 year, only 
one tumor was diagnosed among the 30 GTCs-treated men, whereas nine cancers 
were found among the 30 placebo-treated men. 
Unlike the experimental evidence, the few observational studies of flavonoids 
and PCa conducted to date mostly reported null results [15-20]. Observational studies 
of tea and PCa were generally inconclusive [5, 21, 22]. It is important to note that most 
of these studies were limited by a small number of cases and that studies of tea 
consumption and PCa risk were often limited by a narrow range of tea intake. An 
additional consideration is that while risk factors for PCa are likely to differ for 
subgroups based on disease stage or aggressiveness [23], few of these prior 
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investigations considered the clinical or pathologic manifestations of PCa in the study 
design and interpretation. 
We therefore investigated the associations between dietary flavonoid intake, 
black tea consumption, and PCa risk in a large cohort from the Netherlands with a 
relatively wide range of these exposures. We evaluated intake of total catechin, total 
flavonol, and specific catechins (catechin and epicatechin) and flavonols (quercetin, 
kaempferol, and myricetin). We investigated risk of both overall PCa and PCa 
subgroups based on disease stage since associations may be different in these 
subgroups. 
Methods 
Study population 
The Netherlands Cohort Study (NLCS) is an ongoing prospective cohort study that 
started in September 1986. The NLCS includes 58,279 men, aged 55 to 69 years at 
baseline. All cohort members completed a baseline questionnaire [24]. Follow-up for 
incident cancer has been established by record linkage to the Netherlands cancer 
registries and the pathology registry PALGA [25]. The completeness of cancer follow-up 
through linkage with these cancer registries was assessed to be at least 96% [26]. The 
NLCS uses a case−cohort approach for data processing and analysis; case subjects were 
derived from the entire cohort and the person-time experience was estimated from a 
subcohort randomly sampled from the full cohort at baseline [27]. 
The present study is based on a follow-up of 17.3 years (September 1986 to 
December 2003). In our analysis, we excluded all cases with prevalent cancer other 
than skin cancer at baseline. We also excluded subjects with incomplete or 
inconsistent dietary data, according to criteria described previously [28], and subjects 
with missing information on tea consumption (Figure 5.1). Our study included 3,362 
incident PCa cases and 2,128 subcohort members. 
The NLCS has been approved by the institutional review boards of the TNO 
Nutrition and Food Research Institute (Zeist, the Netherlands) and Maastricht 
University (Maastricht, the Netherlands). 
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Figure 5.1  
Flow diagram of male subcohort members and prostate cancer cases of the Netherlands Cohort Study, 
1986−2003a 
Abbreviations: NCR, Netherlands cancer registry; PALGA, Netherlands nationwide pathology registry.  
a Non-advanced prostate cancers were stage T1−2 and N0 and M0 at diagnosis. Advanced prostate cancers 
were stage T3−4, N+, or M1 at diagnosis. 
Classification of prostate cancer cases 
We evaluated PCa subgroups based on disease stage. Advanced prostate cancers 
(International Union Against cancer (UICC) [29] stage III/IV) included tumors with stage 
T3−4, N+, or M1 at diagnosis. Stage IV (UICC) prostate cancers were a subset of 
advanced prostate cancers and included tumors with stage T4, N+, or M1 at diagnosis. 
Prostate cancers that were not identified as advanced cancers were classified as non-
advanced prostate cancers (UICC stage I/II; stage T1−2 and N0 and M0 at diagnosis). 
Our study included 1,164 advanced cancers and 1,986 non-advanced cancers (Figure 
5.1). Of all advanced prostate cancers, 736 were stage IV prostate cancers. A small 
number of cases had missing data on tumor stage (n = 212) and could not be classified 
as either advanced or non-advanced PCa. 
Exposure assessment 
Dietary intake of study participants were derived from a baseline 150-item semi-
quantitative food frequency questionnaire (FFQ) that is described in greater detail 
elsewhere [24, 28, 30]. This dietary assessment was part of a larger questionnaire that 
also included questions about lifestyle and health. 
Flavonoid contents in foods and beverages were derived from food composition 
tables based on data gathered in the Netherlands [31-34]. Major flavonoid subgroups 
The Netherlands Cohort Study
Subcohort sampled at baseline
Exclusion if incomplete or inconsistent dietary data
Record linkage with NCR and PALGA
Prostate cancers [non-advanced; advanced]
nmen = 58,279
Exclusion of prevalent cancer cases at baseline
Exclusion if missing data on tea consumption
n =3,667 [n = 2,142; n = 1,290]
n =3,451 [n = 2,039; n = 1,196]
n =3,362 [n = 1,986; n = 1,164]
n = 2,336
n = 2,191
n = 2,128
n = 2,411
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in our study are catechin and flavonol. Specific catechins in our study are (+)-catechin 
and (−)-epicatechin. The catechins (+)-gallocatechin, (−)-epigallocatechin, (−)-
epicatechin gallate, and (−)-epigallocatechin gallate are found almost exclusively in tea 
and are therefore not evaluated separately. Specific flavonols in our study are 
quercetin, kaempferol, and myricetin. Flavones are another flavonoid subclass and the 
only flavone consumed in our population is luteolin. Since flavones are a minor group 
of flavonoids compared with the flavonols, the term flavonols will be used here for the 
sum of both groups. 
With regard to tea consumption, cohort members were asked whether they 
drank tea and, if so, how many cups per day. The type of tea was not specified but this 
population rarely drank tea other than black tea [35]. Based on a pilot study, the 
standard cup size was assumed to be 125 ml [35]. 
Statistical analyses 
We used Cox proportional hazards regression to obtain hazard ratios (HRs) and 
corresponding 95% confidence intervals (CIs) for the association between quartiles of 
flavonoid intake and categories of black tea consumption and risk of PCa and PCa 
subgroups based on disease stage. Cut-off points for each quartile were based on the 
distribution of each variable in the subcohort. Tests for linear trend were carried out 
by taking the median values of all quartiles and modeling intake as a continuous 
variable. All models were adjusted for age at baseline as a continuous variable (years). 
The following factors, which are hypothesized or known to be associated with either 
PCa, flavonoid intake, or black tea consumption, were assessed as potential 
confounding variables: family history of PCa among first degree relatives (yes/no), 
smoking status (never, former, current), duration of smoking (years), frequency of 
smoking (cigarettes/day), non-occupational physical activity (≤30, >30−60, >60−90, >90 
minutes/day), BMI (<23, 23−<25, 25−<27, 27−<30, ≥30), height (cm), diabetes (type I or 
II, yes/no), education level (primary school, lower vocational, high school, higher 
vocational/university), and intake of energy (kcal/day), alcohol (g/day), calcium 
(g/day), lycopene (mg/day), vitamin E (mg/day), red meat (g/day), and coffee 
(cups/day). We evaluated whether adding any of these variables to the age-adjusted 
model changed the hazard ratio by at least 10%. Because none did so, our final model 
was adjusted for age at baseline only. We additionally present our primary findings 
adjusted for all these potential confounders to show that addition of those factors did 
not appreciably alter the results. The proportional hazards assumption was tested 
using the scaled Schoenfeld residuals [36]. Standard errors were estimated by using 
the robust Huber-White sandwich estimator, to account for additional variance 
introduced by sampling from the cohort [37]. 
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To examine the influence of pre-clinical disease on our results, we repeated the 
analyses while excluding the first two years of follow-up. To investigate possible 
confounding due to differences in PSA testing, we stratified by time period to 
determine whether the observed associations were different in an early period when 
PSA testing was not yet introduced in the Netherlands (1986−1994) and a late period 
when PSA testing was used in clinical practice (1995−2003) in the Netherlands.  
All P-values were two-sided, with a P-value less than 0.05 considered to be 
statistically significant. Analyses were performed using STATA software (release 11, 
STATA Corporation, College Station, TX). 
Results 
The baseline characteristics of our study population are shown in Table 5.1. Compared 
with subcohort members, PCa cases were more likely to have a first degree relative 
affected with PCa and less likely to have a history of diabetes.  
Important sources of flavonoids in our population are black tea, allium 
vegetables, apples and pears, cabbages, chocolate, legumes, and leafy vegetables 
(Table 5.2). Black tea is by far the major source of total catechin (80%), kaempferol 
(70%), and myricetin (78%) and contributed significantly to intake of catechin (35%), 
epicatechin (46%), total flavonol (46%), and quercetin (35%). 
We present age-adjusted hazard ratios (HRs) and 95% confidence intervals (CIs). 
Dietary flavonoid intake was not associated with overall or non-advanced PCa risk 
(Table 5.3). Intake of total catechin, epicatechin, kaempferol, and myricetin was 
associated with a decreased risk of stage III/IV or IV PCa and hazard ratios of stage IV 
PCa for the highest versus lowest quartile of intake of total catechin, epicatechin, 
kaempferol, and myricetin were respectively 0.73 (95% CI: 0.57, 0.95), 0.74 (95% CI: 
0.57, 0.95), 0.78 (95% CI: 0.61, 1.00), and 0.71 (95% CI: 0.55, 0.91). 
We investigated associations between black tea consumption and PCa risk. The 
median consumption of black tea in our population is 2 cups per day. Black tea 
consumption was inversely associated with risk of advanced (stage III/IV) and stage IV 
PCa but not with risk of overall and non-advanced (stage I/II) PCa (Table 5.4). The HR of 
advanced PCa for the highest versus the lowest category of black tea consumption (≥5 
versus ≤1 cups/day) was 0.75 (95% CI: 0.59, 0.97) and the HR for an increment of 1 cup 
per day was 0.97 (95% CI: 0.93, 1.01). The HR of stage IV PCa for the highest versus the 
lowest category of black tea consumption (≥5 versus ≤1 cups/day) was 0.67 (95% CI: 
0.50, 0.91) and the HR for an increment of 1 cup per day was 0.95 (95% CI: 0.90, 0.99). 
These associations were similar when adjusted for all potential confounders (HR of 
stage IV PCa for ≥5 versus ≤1 cups/day: 0.67 (95% CI: 0.48, 0.94)). Fruits and vegetables 
contain many antioxidant nutrients other than flavonoids (e.g. vitamin C, lycopene). 
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We studied whether the association between black tea consumption and stage III/IV 
and stage IV PCa was modified by intake of total fruits and vegetables (≤median intake, 
>median intake), but it was not (P for interaction >0.05). 
To examine the influence of preclinical disease on our results, we repeated the 
analyses while excluding the first two years of follow-up, and we observed that the 
results were unchanged. To examine whether confounding by PSA testing might 
explain the associations, we stratified by time period and separately evaluated an early 
period (pre-PSA period: 1986−1994) and a late period (PSA period: 1995−2003). We 
observed that the point estimates were comparable in both time periods and HRs for 
the association between black tea consumption (≥5 versus ≤1 cups/day) and stage IV 
PCa risk in the early and late period were 0.63 (95% CI: 0.41, 0.97) and 0.69 (95% CI: 
0.48, 1.00), respectively.   
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Discussion 
This large prospective study showed that intake of total catechin, epicatechin, 
kaempferol, and myricetin and consumption of black tea were associated with a 
decreased risk of PCa of advanced stage (stage III/IV and IV). None of the exposures 
considered were associated with risk of overall or non-advanced (stage I/II) PCa. These 
associations were robust in that they remained unchanged after exclusion of cases 
diagnosed during the first two years of follow-up. The HRs were similar after 
multivariable adjustment, which implies that there was no substantial confounding by 
any of the additionally included covariables. 
Only few observational studies investigated associations between flavonoid 
intake and PCa risk and most of these reported null results [15-20]. None of these 
studies evaluated PCa subgroups based on tumor characteristics. One small Finish 
prospective cohort study, which included 95 PCa cases, previously showed that 
myricetin intake was inversely associated with overall PCa risk [17]. In our population, 
black tea was by far the major source of myricetin (78%), but in the Finish study 
information on tea consumption was not available because tea consumption in Finland 
is very low. The major source of myricetin in the Finish population was berries. 
A recent meta-analysis of PCa and consumption of black tea (11 studies) and 
green tea (seven studies) showed that green tea but not black tea may have a 
protective effect on PCa [21]. Most studies of green tea were conducted in Asian 
populations. Previous observational studies of black tea consumption and PCa mostly 
reported null results [5, 21], but interestingly, only two small-scale studies considered 
the pathologic manifestations of PCa. One population-based case−control study (87 
aggressive PCa cases) [38] and one prospective cohort study (37 Gleason ≥8 prostate 
cancers) [22] observed no association between black tea consumption and risk of 
aggressive PCa. One prospective cohort study in Japan previously showed that 
consumption of green tea was inversely associated with risk of advanced PCa but not 
overall or localized PCa [39]. This study included 404 incident prostate cancers of 
which 114 were advanced cancers. The multivariable adjusted relative risk for 
advanced PCa for the highest versus the lowest category of green tea consumption (≥5 
versus <1 cups/day) was 0.52 (95% CI: 0.28, 0.96; P for trend = 0.01). This association 
was stronger than the association between black tea consumption and advanced PCa 
risk in our study and one possible explanation for this is the higher concentration of 
catechins in green compared to black tea [7]. 
Tea polyphenols are mainly absorbed from the small intestine and are then 
subject to phase II metabolism, which likely affects their bioavailability [7]. A human 
pre-prostatectomy trial, however, showed that black tea and green polyphenols are 
bio-available in the prostate [40]. Flavonoids have various biological properties that 
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can explain the association with a decreased risk of advanced stage PCa. The most 
widely recognized biological properties of flavonoids are the antioxidant properties [2, 
41], and oxidative stress is believed to be related to prostate carcinogenesis [42, 43]. 
Various antioxidants have been associated with advanced stage PCa [44, 45]. Besides 
that, flavonoids can affect apoptosis, angiogenesis, and inflammatory processes all of 
which play roles in PCa progression [6-11]. 
Black tea contains a high concentration of theaflavins and thearubigins, which are 
polymeric polyphenols. These compounds are formed from catechins during 
fermentation of tea leaves and might also have anticarcinogenic activity. There are 
studies using cell lines that showed that theaflavin and thearubigin inhibit PCa growth 
[46, 47]. However, because of the limited bioavailability of these compounds it is 
believed that they generally do not contribute to the chemopreventive effects of black 
tea in vivo [7]. 
In our study we did not obtain information on infusion time of tea or tea 
strength. Such additional information could have provided us with a more precise 
estimation of daily flavonoid intake. Another possible limitation is that misclassification 
may have occurred in the assignment of flavonoid levels to the foods reported. 
Flavonoid contents are known to vary greatly by variety, thus individual preferences 
for particular varieties of foods would lead to misclassification. Our analyses were 
performed by using baseline FFQ data and it is thus possible that changes in black tea 
consumption after 1986 resulted in attenuation of our risk estimates. Inaccuracy of 
recall of tea consumption as such also may be a source of bias. Unfortunately, we had 
no separate data on tea available from the validation study of our food-frequency 
questionnaire [28], but considering the simplicity of the question on tea and the small 
number of blanks encountered, we would expect that the accuracy of recall was even 
better than average. Another limitation is that we had no information on PSA testing, 
which might be a confounder. We however showed that the observed associations 
were similar in an early period when PSA testing was not yet introduced in the 
Netherlands (1986−1994) and a late period when PSA testing was used in clinical 
practice in the Netherlands (1995−2003). Besides that, it is important to note that in 
the Netherlands PSA testing was introduced relatively slowly in comparison to other 
high-income countries and has never been used for systematic screening or case 
finding [48]. In 2001 in the Netherlands only 14% of men over 45 years of age had a 
PSA measurement in the previous 5 years [48]. Based on this evidence it is unlikely that 
PSA testing is an explanation for the observed associations in our study. 
Our study has several strengths including its prospective design, large sample 
size, and long and nearly complete follow-up. The range of black tea intake in our 
cohort was wide. We had data on tumor stage for most cases, which made it possible 
to stratify by disease stage, and our study included a large number of advanced 
92 
prostate cancers. Our FFQ contained questions about all important sources of 
flavonoids and we have data on many potential confounding variables. 
In conclusion, men with a high intake of black tea, total catechin, epicatechin, 
kaempferol, and myricetin had a reduced risk of PCa of advanced stage. These findings 
need to be reproduced in other large-scale observational studies with comprehensive 
data on flavonoid contents in foods and beverages and evaluation of PCa subgroups 
based on pathologic manifestations. 
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Abstract 
Background 
Increased oxidative stress has been linked to prostate cancer (PCa). We investigated 
oxidative stress-related genetic variants in relation to advanced PCa risk and examined 
potential interactions with pro- and antioxidant exposures. 
Methods 
A case−cohort analysis was conducted in the Netherlands Cohort Study, which 
included 58,279 men aged 55−69 years. Cohort members completed a baseline 
questionnaire and provided toenail clippings, which were used to determine selenium 
levels and to isolate DNA for genotyping. Incident advanced PCa cases, defined on the 
basis of TNM stage at diagnosis, were identified during 17.3 years of follow-up. The 
analysis included 14 oxidative stress-related gene variants and 11 pro- and antioxidant 
dietary and lifestyle factors. Cox regression models were used and false discovery rate 
(FDR) was applied to adjust for multiple testing. 
Results 
Complete genotyping data were available for 952 advanced (stage III and IV) PCa cases 
and 1,798 subcohort members. CAT rs1001179 was associated with stage III/IV and 
stage IV PCa risk, with HRs per minor allele of 1.16 (95% C: 1.01, 1.33) and 1.25 (95% 
CI: 1.07, 1.46), respectively. We tested 151 gene−environment interactions in relation 
to both stage III/IV and IV PCa risk. Seven interactions were statistically significant after 
adjusting for multiple testing (FDR Q-value <0.20); for stage III/IV PCa these involved 
intake of β-carotene (GPX1 rs17650792, hOGG1 rs1052133) and heme iron (GPX1 
rs1800668 and rs3448), and for stage IV PCa these involved intake of catechin (SOD2 
rs4880) and heme iron (hOGG1 rs1052133, SOD1 rs10432782).  
Conclusion 
This study of advanced PCa risk showed a marginal association with a CAT 
polymorphism and seven novel gene−environment interactions in the oxidative stress 
pathway. 
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Introduction 
Oxidative stress results from an imbalance between antioxidant protection and 
reactive oxygen species (ROS) produced by pro-oxidants [1-3]. ROS are strong oxidizing 
agents that cause damage to cellular constituents when levels are elevated [1, 2]. 
Antioxidants include endogenous enzymes (e.g., superoxide dismutase, SOD; catalase, 
CAT; and glutathione peroxidase; GPX) and exogenous dietary nutrients (e.g., vitamins 
C and E, carotenoids, flavonoids, selenium) [4, 5]. Important pro-oxidant factors 
include inflammatory processes and the mitochondrial electron transport chain, but 
also exogenous exposures such as cigarette smoking, dietary iron, and radiation [2, 4]. 
Oxidative stress becomes more common with advancing age [6, 7], and has been 
implicated in age-related degenerative diseases, including prostate cancer (PCa) [8-11]. 
Previous epidemiological studies on antioxidant nutrients and PCa risk have 
generated mixed results [12]. More than fifty observational (prospective and 
case−control) studies investigated the associations of the major dietary antioxidants 
vitamins C and E, lycopene, β-carotene, and selenium. Results from these studies 
showed that most antioxidants were not associated with overall or advanced PCa risk 
[12, 13], with the exception of selenium, which has been inversely associated with 
overall and advanced PCa risk in many studies [14], including our study [15, 16]. 
Secondary results from two randomized controlled trials, the Alpha-Tocopherol, Beta-
Carotene Cancer Prevention (ATBC) study [17], and the Nutritional Prevention of 
Cancer (NPC) study [18], showed PCa risk reductions for vitamin E and selenium, 
respectively. These findings led to the design of the Selenium and Vitamin E Cancer 
Prevention Trial (SELECT), which however showed no protective effect of both 
nutrients [19]. There have been a number of observational studies that investigated 
pro-oxidant exposures such as smoking, alcohol, and dietary iron in relation to overall 
and advanced PCa risk, but these studies do not support an association [20-24]. 
Genetic variation in genes related to oxidative stress may influence PCa risk. 
These genes include those encoding pro- and antioxidant enzymes but also other 
oxidative stress-related genes (e.g., oxidative DNA damage repair). Several variants in 
these genes have been identified that have potential functional consequences [25-30]. 
Candidate gene-association studies investigated these genetic variants in relation to 
PCa risk and showed significant associations for variants in different genes such as 
SOD2, PON1, GPX1, NOS2A, NOS3, and hOGG1 [25-30]. Genome-wide association 
studies of PCa, however, did not identify risk variants in major oxidative stress-related 
genes [31]. Besides having a main effect on PCa risk, oxidative stress-related gene 
variants may also interact with pro- and antioxidant exposures and potentially modify 
their effects. This has been investigated in a small number of studies that focused on 
specific a priori defined gene−environment interactions. These studies have produced 
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statistically significant results, including the interactions between SOD2 and selenium 
[32], SOD2 and iron [20], and hOGG1 and α-tocopherol [29].  
In the present study, we evaluated 14 genetic variants in oxidative stress-related 
genes. The gene variants are single nucleotide polymorphisms (SNPs) reported in prior 
studies to have either a functional effect or an association with PCa risk. We 
investigated associations between these SNPs and advanced PCa risk and examined 
potential gene−environment interactions with major pro- and antioxidant exposures. 
We specifically studied advanced PCa, which is a subtype of PCa associated with a poor 
prognosis that is, therefore, clinically relevant [33]. 
  
Methods 
Study population and design 
The prospective Netherlands Cohort Study included 58,279 men, aged 55 to 69 years 
at baseline in September 1986. Study participants completed a baseline questionnaire 
on dietary habits, lifestyle, health, and several other potential cancer risk factors [34]. 
Approximately 81% of cohort members provided toenail clippings from all ten toes, 
which were used to determine toenail selenium levels and to isolate DNA for 
genotyping. Cancer cases were identified by annual record linkage to the Netherlands 
Cancer Registry and the Dutch Pathology Registry [35]. The completeness of follow-up 
through linkage with these registries was assessed to be at least 96% [36]. The 
Netherlands Cohort Study employs the case−cohort design [37]; cases are derived from 
the entire cohort and the person-time experience is estimated from a subcohort 
randomly sampled from the full cohort at baseline (n = 2,411). All participants with 
prevalent cancer other than skin cancer at baseline were excluded (approximately 3%). 
Figure 1 shows a flow diagram of cases and subcohort members. The Netherlands 
Cohort Study has been approved by the institutional review boards of the TNO 
Nutrition and Food Research Institute (Zeist, the Netherlands) and Maastricht 
University (Maastricht, the Netherlands).  
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Figure 6.1 
Flow diagram of advanced prostate cancer cases and subcohort members, Netherlands Cohort Study, 
1986−2003 
Abbreviations: NCR, Netherlands Cancer Registry; PALGA, Dutch Pathology Registry. 
a Advanced prostate cancer was defined as T3−4, N+, or M1 at diagnosis (International Union Against Cancer, 
stage III/IV). On average, 63% of advanced cases were stage IV prostate cancer (stage T4, N+, or M1 at 
diagnosis).  
b Analysis 1 is on the associations between oxidative stress-related genetic variants and advanced prostate 
cancer risk. The analysis included 952 cases and 1,798 subcohort members.  
c Analysis 2 is on potential interactions between oxidative stress-related genetic variants and pro- and 
antioxidant intake on advanced prostate cancer risk. The analysis included 903 cases and 1,707 subcohort 
members.  
d Analysis 3 is on potential interactions between oxidative stress-related genetic variants and toenail 
selenium levels on advanced prostate cancer risk. The analysis included 817 cases and 1,048 subcohort 
members. A smaller version of the subcohort (70%) was used for this analysis. 
Ascertainment and classification of participants who developed prostate cancer 
During 17.3 years of follow-up (September 1986 to December 2003), 3,667 incident 
PCa cases (ICD-O-3 code C61) were identified. PCa cases were classified on the basis of 
Tumor-Node-Metastasis (TNM) staging (pathological TNM, where available, or clinical 
TNM) [38]. In the present analysis we specifically evaluated advanced PCa 
(International Union Against Cancer, stage III and IV [38]), which included tumors with 
T3−4, N+, or M1 at diagnosis (n = 1,290; Figure 1). Stage IV PCa is a subset of advanced 
PCa and was stage T4, N+, or M1 at diagnosis (n = 817). A number of cases had missing 
data on tumor stage (n = 235) and were excluded from the analysis.  
DNA isolation, gene variant selection, and genotyping 
DNA was isolated from available toenail samples using a phenol-chloroform extraction 
[27, 39]. We previously showed that toenail samples are a long-term stable source of 
DNA for genotyping [39]. The minimum amount of toenail material required for DNA 
extraction was 4 mg and we excluded participants who provided less. Toenail DNA was 
successfully isolated for 1,030 cases and 1,885 subcohort members (>99.9% successful 
DNA isolation; Figure 1).  
We selected single nucleotide polymorphisms (SNPs) in oxidative stress-related 
genes reported in prior studies to have a functional effect (e.g., altered gene 
expression or enzyme activity) or an association with PCa risk. The following SNPs were 
selected: CAT rs1001179 [40], GPX1 rs17650792 [27], GPX1 rs1800668 [27], GPX1 
rs3448 [41], hOGG1 rs1052133 [29], NOS2A rs2297518 [28], NOS2A rs9282801 [28], 
NOS3A rs1799983 [28], NQ1 rs1800566 [42], PON1 rs662 [26], PON1 rs854560 [26], 
SOD1 rs10432782 [43], SOD2 rs4816407 [43], and SOD2 rs4880 [25]. Selection of 
genetic variants was restricted to those with a minor allele frequency of at least 10%. 
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MPO rs2333227 was not included in the final SNP selection because it was not possible 
to design unique primers for the SNP given the other SNPs selected in our study. 
SNP genotyping was done by designing polymerase chain reaction (PCR) assays 
and extension primers with the use of MassARRAY software, version 4.0 (Sequenom 
Inc., Hamburg, Germany). PCR and extension reactions were performed according to 
the manufacturer’s instructions, and extension product sizes were determined by mass 
spectrometry with the use of the iPLEX Gold system (Sequenom Inc., Hamburg, 
Germany). 
Quality control included genotyping of blind duplicate samples (n = 143, or 5% of 
all genotyped samples), which revealed >99% agreement on genotyping calls across all 
SNPs assayed. Samples with a sample call rate (i.e. percentage of called SNPs per 
sample) of less than 95% were excluded (78 cases and 87 subcohort members) and 952 
cases and 1,798 subcohort members had complete genotyping data (Figure 6.1). All 
SNPs had >99% genotype completion rates (i.e. percentage of non-missing samples per 
SNP). None of the SNPs violated Hardy-Weinberg equilibrium (P >0.05).  
Exposure assessment 
A baseline food frequency questionnaire (FFQ) was used to assess dietary pro- and 
antioxidant intake [44, 45]. The FFQ was part of a larger questionnaire that also 
included questions regarding various other factors such as lifestyle, family history of 
cancer, and health. We selected and studied the major dietary antioxidant nutrients: 
β-carotene, lycopene, catechin, vitamin C, and vitamin E (intake in mg/day); and the 
major pro-oxidant factors: heme iron (intake in mg/day), alcohol (intake in g/day), and 
smoking status (never, former, current) [21]. We also evaluated an antioxidant score 
(AOS) and oxidative balance score (OBS), which have been investigated in previous 
analyses [46, 47], including our study [21]. In our study, the AOS is the sum of quartile 
scores (Q1 = 0; Q2 = 1; Q3 = 2; Q4 = 3) of intake of β-carotene, lycopene, catechin, 
vitamin C, and vitamin E. The OBS additionally includes heme iron intake (Q1 = 3; Q2 = 
2; Q3 = 1; Q4 = 0), alcohol consumption (abstainer = 3; 0.1−4 g/day = 2.25; 5−14 g/day 
= 1.5; 15−29 g/day = 0.75; ≥30 g/day = 0), and smoking status (never = 3, former = 1.5, 
current = 0); these prooxidants are scored in the opposite way to the antioxidants.  
The FFQ was validated and tested for reproducibility. Comparison with a 9-day 
dietary record showed that it was able to rank subjects adequately according to intake 
of the food groups and nutrients investigated [44]. The FFQ was also found to be a 
good indicator of nutrient intake over a period of at least 5 years [45]. Concentrations 
of specific nutrients in foods and beverages were derived from food composition 
tables based on data gathered in the Netherlands [21, 48]. We excluded participants 
with incomplete or inconsistent dietary data, according to criteria described 
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previously; 903 advanced PCa cases and 1,707 subcohort members had complete 
genotyping and dietary intake data (Figure 6.1) [44]. 
Toenail selenium measurements 
Selenium concentrations were measured in toenail samples using instrumental 
neutron activation analysis of the 
77m
Se isotope [15, 16]. Each sample went through six 
cycles of 17-second irradiation at a thermal neutron flux of 3 x 10
16
 m
-2
s
-1
, 3-second 
decay, and 17-second counting at 1 cm from a 40% germanium detector. The accuracy 
of the analysis was checked by a certified bovine liver standard (Standard Reference 
Material 1577b of the US National Institute of Standards and Technology). We 
excluded participants who provided a toenail sample of less than 10 mg because the 
selenium determination could otherwise be unreliable. A smaller version of the 
subcohort was used for the toenail selenium determination (70%).The final analysis 
included 817 cases and 1,048 subcohort members who had complete toenail selenium 
data and genotyping data (Figure 6.1). 
Statistical analysis 
The risk of advanced (stage III/IV and IV) PCa in relation to oxidative stress-related 
genetic variants was assessed by age-adjusted Cox proportional hazards regression 
models. The SNPs were analyzed under a co-dominant and log-additive genetic model. 
The standard errors were estimated by using the robust Huber-White sandwich 
estimator to account for additional variance introduced by sampling from the cohort 
[49]. The proportional hazards assumption was tested using the scaled Schoenfeld 
residuals [50]. In none of the analyses the proportional hazards assumption was 
violated. The associations between the three GPX1 SNPs (rs17650792, rs1800668, and 
rs3448) and advanced PCa risk have been reported previously by our group [27], and 
are therefore not part of the present analysis.  
We tested for multiplicative interactions between pro- and antioxidant exposures 
(quartiles or categories) and genotypes (dominant model) on advanced PCa (stage 
III/IV and IV) risk by using cross-product terms in the regression models and the Wald 
statistic. Exposure quartiles were based on the distribution of the variable in the 
subcohort. We used a dominant genetic model to increase study power, unless there 
was evidence of a recessive association in our study or previous studies. Interactions 
between GPX1 SNPs (rs17650792, rs1800668, and rs3448) and toenail selenium levels 
on advanced PCa risk have been reported previously by our group [27], and are 
therefore not part of the present analysis. The following factors were assessed as 
potential confounding variables: family history of PCa among ﬁrst-degree relatives 
(yes/no), smoking status (never, former, or current), duration of smoking (years), 
frequency of smoking (cigarettes/day), non-occupational physical activity (≤30, 
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>30−60, >60−90, >90 min/day), body mass index (<23, 23−<25, 25−<27, 27−<30, ≥30), 
height (cm), diabetes (type I or II, yes/no), education level (primary school, lower 
vocational, high school, higher vocational/university), and intakes of energy (kcal/day) 
and calcium (g/day). These variables were identiﬁed as confounders when adding 
them, one at a time, to the age-adjusted model changed the point estimates by at 
least 10%, which was the case for none of these variables.  
To account for multiple statistical testing when identifying gene−environment 
interactions (total number of tests performed = 302) we calculated false discovery rate 
(FDR) Q-values [51-53]. The FDR Q-value represents the expected proportion of false-
positive results when testing for signiﬁcance. FDR Q-values are calculated by 
multiplying the P-value for interaction (calculated from each test from regression 
models) by the number of tests performed; and then dividing the multiplication by the 
rank order of each P-value (where rank order 1 is assigned to the smallest P value) [53, 
54]. We calculated an FDR Q-value for each pro- and antioxidant-specific interaction 
accounting for the total number of SNPs under investigation. We used an FDR Q-value 
threshold of 0.20, which has been suggested for candidate gene studies [52, 53]. A 
more stringent threshold is often used in genome-wide association studies, which 
typically do not use prior (mechanistic) information to select candidate genes [55]. In 
this manuscript we presented SNP−environment interactions with a P for multiplicative 
interaction <0.05. For each statistical interaction we report the FDR Q-value and the 
hazard ratios (HRs) from the stratified analysis using a single reference category 
(lowest quartile or category of exposure and the common homozygote genotype).  
All tests were two-sided with a P-value <0.05 considered to be statistically 
significant. Analyses were performed using STATA software (release 12, STATA 
Corporation, College Station, TX). 
Results 
Table 1 shows the baseline characteristics of advanced PCa cases and subcohort 
members. Compared with subcohort members, cases were more likely to have a ﬁrst-
degree relative with PCa and less likely to have a history of diabetes.  
Table 6.2 shows the associations between oxidative stress-related genetic 
variants and advanced PCa risk. CAT rs1001179 was associated with both stage III/IV 
and stage IV PCa risk, with HRs per minor A allele of 1.16 (95% CI = 1.01, 1.33; P for 
trend = 0.032) and 1.25 (95% CI = 1.07, 1.46; P for trend = 0.006), respectively. No 
other SNPs were associated with advanced PCa risk. 
Table 6.3 shows the statistical interactions between oxidative stress-related 
genetic variants and pro- and antioxidant intake and status on advanced (stage III/IV 
and IV) PCa risk. We tested 151 SNP−environment interactions in relation to both stage 
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III/IV and IV PCa risk and identified 15 statistically significant multiplicative interactions 
(stage III/IV PCa, n = 8; stage IV PCa, n = 7). Seven of these interactions met the FDR Q-
value <0.20 criterion; for stage III/IV PCa these involved intake of β-carotene (GPX1 
rs17650792, hOGG1 rs1052133) and heme iron (GPX1 rs1800668 and rs3448), and for 
stage IV PCa these involved intake of catechin (SOD2 rs4880) and heme iron (hOGG1 
rs1052133, SOD1 rs10432782). Stratified analyses using a single reference category 
(common homozygote genotype and lowest quartile of intake) showed: lowered risk 
for men with the AA genotype of GPX1 rs17650792 in the third quartile of β-carotene 
intake (HR = 0.61; 95% CI: 0.40, 0.93); elevated risk for men carrying the G allele of 
hOGG1 rs1052133 in the first (HR = 1.49; 95% CI: 1.04, 2.12) and third quartile of β-
carotene intake (HR = 1.51; 95% CI: 1.08, 2.11); lowered risk for men with the AA 
genotype of GPX1 rs1800668 in the third quartile of heme iron intake (HR = 0.53; 95% 
CI: 0.34, 0.82); elevated risk for men carrying the G allele of hOGG1 rs1052133 in the 
first (HR = 1.48; 95% CI: 1.00, 2.18) and second quartile of heme iron intake (HR = 1.66; 
95% CI: 1.12, 2.46); and elevated risk for men carrying the G allele of SOD1 rs10432782 
in the first (HR = 2.14; 95% CI: 1.36, 3.34) and second quartile of heme iron intake (HR 
= 1.61; 95% CI: 1.03, 2.51). Of all 15 interactions, two displayed a decrease in risk over 
exposure categories. The first interaction was between SOD2 rs4880 and toenail 
selenium level on advanced PCa risk (P for interaction = 0.025; FDR Q = 0.28); 
compared with men with the common TT genotype in the lowest selenium quartile, 
carriers of the minor C allele (CT + CC) in the highest selenium quartile had an HR of 
0.44 (95% CI: 0.28, 0.69). The second interaction was between GPX1 rs17650792 and 
catechin intake on stage IV PCa risk (P for interaction = 0.042; FDR Q = 0.29); among 
men with the common homozygote AA genotype those in the highest versus lowest 
quartile had an HR of 0.38 (95% CI: 0.23, 0.64). 
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Discussion 
In this large prospective study we evaluated oxidative stress-related genetic variants in 
relation to advanced PCa risk and examined potential interactions with pro- and 
antioxidant intake and status. The study showed an association between CAT 
rs1001179 and advanced PCa risk. Marginal associations were not observed for any of 
the other tested SNPs. Of the observed 15 statistically significant multiplicative 
gene−environment interactions, 7 retained significance after multiple comparison 
adjustment using an FDR Q-value threshold of 0.20. These interactions were on either 
stage III/IV or stage IV PCa risk and involved intake of β-carotene (GPX1, hOGG1), 
catechin (SOD2), and heme iron (GPX1 (two SNPs), hOGG1, SOD1). 
Catalase is an endogenous antioxidant enzyme that neutralizes hydrogen 
peroxide, a type of ROS, by converting it to water and oxygen [5]. The enzyme plays an 
integral role in antioxidant defense against oxidative stress. CAT rs1001179 (A/G) (also 
known as -262 C/T) is a common polymorphism located in the promoter region of the 
gene [56]. A number of studies investigated associations between CAT rs1001179 and 
risk of cancer but mostly reported null findings [30]. Only few studies investigated this 
SNP in relation to PCa risk. In a nested case−control study (533 cases and 1,470 
controls), Choi et al. showed no association between the SNP and overall PCa risk [40]. 
Recently, however, a small case−control study of PCa in Turkey (155 cases and 195 
controls) showed that CAT rs1001179 was associated with overall PCa risk; men with 
the homozygote rare genotype compared to the homozygote common genotype had 
an HR of 1.57 (95% CI = 1.09, 1.71) [57]. The authors also showed that among PCa 
cases the homozygote rare genotype was associated with advanced stage disease. Our 
analysis provides evidence of a role for CAT rs1001179 in PCa by showing that the rare 
allele of the SNP was associated with increased risk of advanced PCa. This finding is 
biologically plausible because the rare allele of CAT rs1001179 has been associated 
with lower catalase activity [58, 59]. A reduced catalase activity may result in deficient 
antioxidant protection against oxidative stress, which could potentially translate into a 
higher risk of developing PCa. We found no evidence of a marginal association for the 
ten other SNPs investigated. This is striking because we selected candidate SNPs that 
have been associated with PCa risk in previous studies. The different outcome may 
result in part from the fact that we investigated advanced PCa and the prior studies 
mostly investigated overall PCa. 
The significant gene−environment interactions (on stage III/IV or IV PCa) in our 
study involved intake of β-carotene (GPX1 rs17650792, hOGG1 rs1052133), catechin 
(SOD2 rs4880), and heme iron (GPX1 rs1800668 and rs3448, hOGG1 rs1052133, SOD1 
rs10432782). These interactions, which have not been reported before, met the FDR 
Q-value <0.20 criterion. The risk pattern of the interactions was unclear and could not 
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be interpreted in terms of a dose−response relationship. We observed a significant 
altered risks for men in the third quartile of β-carotene and heme iron intake (GPX1, 
hOGG1) and evidence of a genotype effect (hOGG1, SOD1) for men with low heme iron 
intake. None of the statistical interactions showed a dose−response pattern that 
involved a distinct decrease or increase in risk over exposure categories. A number of 
epidemiological studies investigated associations of these nutrients (intake or levels) 
with PCa risk; and they generally do not support an association for β-carotene or heme 
iron [12, 20-22]. Although our group previously showed that higher catechin intake 
was associated with lower risk of advanced PCa [48], few other studies investigated 
the relationship and they generally do not support an association [60]. Given the 
limited evidence of an association between these dietary nutrients and (advanced) PCa 
risk, as well as that few other studies comprehensively evaluated oxidative stress-
related genetic variation in relation to pro- and antioxidant exposure and PCa risk; the 
positive results in this study require replication. 
While the seven statistically significant interactions did not involve a clear 
dose−response pattern, two other multiplicative interactions (P-value <0.05), that 
were however not significant after multiple testing correction (FDR Q-value >0.20), did 
involve a dose−response pattern. The risk pattern showed a decrease in risk over 
antioxidant exposure categories in one genotype subgroup but not the other. The first 
interaction was between selenium levels and SOD2 rs4880 on stage III/IV PCa risk and 
involved a 56% lower risk for men carrying the C allele in the highest quartile of 
selenium. This interaction has been reported previously in a nested case−control study 
in the Physicians’ Health Study, showing a similar risk pattern as in our study [32]. The 
interaction is supported by mechanistic data and possibly results from an enzyme 
imbalance between SOD2 and GPX, which is selenium-dependent and removes 
hydrogen peroxide produced by SOD2 [61, 62]. The second interaction was between 
catechin intake and GPX1 rs17650792 on stage IV PCa risk and involved a 62% lower 
risk for men with the homozygote AA genotype in the highest quartile of intake. As far 
as we know, there is no mechanistic data supporting this novel interaction. 
Oxidative stress has been hypothesized to play an important role in PCa [9-11]. To 
shed additional light on this link we searched for gene−environment interactions 
between well-known oxidative stress-related gene variants and major pro- and 
antioxidant exposures. This type of hypothesis-driven pathway analysis is important to 
discover gene−environment interactions. Investigating interactions in gene-association 
studies with larger numbers of SNPs, including genome-wide association studies 
(GWAS), remains challenging because of the very large number of tests required. The 
most effective way to apply and detect interactions in the context of GWAS remains 
unresolved [63]. 
114 
The most important strengths of our study include its prospective design, 
population-based approach, and long and nearly complete follow-up of the study 
population through linkage to cancer registries. We specifically evaluated advanced 
stage PCa because these cancers have a poor prognosis and are therefore clinically 
relevant [33]. Intake of selenium cannot be accurately estimated via an FFQ because of 
variations in the selenium content of soil and concomitant variability in the selenium 
content of foods [14]. We therefore used toenail selenium for exposure monitoring, 
which reflects long-term selenium intake [64]. 
Our study has some limitations. First, measurement of dietary intake using 
questionnaires may result in misclassiﬁcation and potentially attenuated risk 
estimates, even though the study participants under study (aged 55 to 69 years) had 
relatively stable diets. Second, for most genes in our study we only selected 1 or 2 
SNPs. The selected candidate SNPs were reported in prior studies to have a functional 
effect or an association with PCa risk and we may therefore have potentially missed 
important SNPs that modify advanced PCa risk. 
In conclusion, this large prospective study on advanced PCa risk showed an 
association with a CAT polymorphism and identified seven novel statistically significant 
gene−environment interactions. Additional well-powered gene−association studies are 
needed to confirm these findings. 
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Chapter 7: Discussion  
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7.1 Main study findings 
First, we investigated associations between selenium levels measured in toenail 
samples and advanced PCa risk and showed that men with the highest selenium levels 
had a more than 60% lower risk compared to men with the lowest levels (Chapter 2; 
Table 7.1). Second, we studied common genetic variation in the major selenoprotein 
genes SEPP1 (5 tagging SNPs) and GPX1 (3 tagging SNPs) in relation to advanced PCa 
risk and examined potential interactions with toenail selenium levels (Chapter 3; Table 
7.2). The analysis showed that one SEPP1 polymorphism and two GPX1 polymorphisms 
were associated with advanced PCa risk. Toenail selenium levels were inversely 
associated with advanced PCa risk independently of common genetic variation in 
SEPP1 and GPX1. Third, we studied intake of other antioxidant nutrients and pro-
oxidant exposures (individually and using combined scores) in relation to PCa risk 
(Chapters 4, 5). Results of these analyses are summarized in Table 7.1. While most 
exposure variables were not associated, intake of specific flavonoids (i.e., catechin, 
epicatechin, myricetin, and kaempferol) and consumption of black tea (a major source 
of flavonoids) were associated with a modest decrease in risk of advanced PCa. Finally, 
we studied candidate oxidative stress-related genetic variants in relation to advanced 
PCa risk and examined potential interactions with pro- and antioxidant exposures (No. 
of gene variants = 14; No. of exposure variables = 11) (Chapter 6). The results of these 
analyses are summarized in Table 7.2. We found that a CAT polymorphism was 
associated with advanced PCa risk and identified seven statistically significant gene–
environment interactions (P-value <0.05 and FDR Q-value <0.20), which involved 
intake of β-carotene (GPX1, hOGG1), catechin (SOD2), and heme iron (GPX1 (2 SNPs), 
hOGG1, SOD2). 
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Table 7.1 
Pro- and antioxidant dietary and lifestyle factors in relation to overall and advanced prostate cancer risk, 
Netherlands Cohort Study, 1986−2003 
Factor Overall prostate cancer Advanced prostate cancera 
Toenail selenium level ↓b ↓ 
Dietary intake of   
 β-carotene − − 
 Total catechin − ↓ 
  Catechin − − 
  Epicatechin − ↓ 
 Total flavonol − − 
  Quercetin − − 
  Kaempferol − ↓ 
  Myricetin − ↓ 
 Lycopene − − 
 Vitamin C − − 
 Vitamin E − − 
 Heme iron − − 
Smoking Status  − − 
Alcohol consumption − − 
Antioxidant Score − − 
Oxidative Balance Score − − 
Black tea consumption − ↓ 
Symbols: ↓, inverse association; −, no association. 
a We used two definitions of advanced PCa: stage III/IV PCa (T3−4, N+, or M1 at diagnosis) and stage IV PCa 
(T4, N+, or M1 at diagnosis).  
b The inverse association between toenail selenium levels and overall PCa risk in the Netherlands Cohort 
Study was not part of the present thesis but has been reported previously [1]. This analysis included 6.3 
years of follow-up. All other results presented in this table were based on 17.3 years of follow-up. 
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Table 7.2 
Associations between genetic variants in selenoprotein and oxidative stress-related genes and advanced 
prostate cancer risk, and interactions with pro- and antioxidant exposures, Netherlands Cohort Study, 
1986−2003a 
Geneb SNP rsID Associated with advanced  
PCa (risk allele)c 
Gene−environment interaction  
(environmental factor)d 
SEPP1 rs13168440 − − 
 rs230813 − − 
 rs230819 − − 
 rs3877899 − − 
 rs7579 Major G − 
    
GPX1 rs17650792 Minor G β-carotene; catechin, heme iron 
 rs1800668 Major C Heme iron 
 rs3448 − Heme iron 
    
CAT rs1001179 Minor A − 
    
hOGG1 rs1052133 − β-carotene; alcohole; heme iron 
    
NOS2A rs2297518 − − 
 rs9282801 − Vitamin C 
    
NOS3A rs1799983 − − 
    
NQ1 rs1800566 − − 
    
PON1 rs662 − − 
 rs854560 − Oxidative balance score 
    
SOD1 rs10432782 − Vitamin C; heme iron 
    
SOD2 rs4816407 − − 
 rs4880 − Selenium; catechin 
Symbols: −, no association or gene−environment interaction.  
a We used two definitions of advanced PCa: stage III/IV PCa (T3−4, N+, or M1 at diagnosis) and stage IV PCa 
(T4, N+, or M1 at diagnosis). 
b SEPP1 and GPX1 SNPs were selected as tagging SNPs (r2 ≥0.8; minor allele frequency ≥10%). All other SNPs 
were candidate SNPs reported in prior studies to have a functional effect or an association with PCa risk (and 
minor allele frequency ≥10%). 
c When marginally associated (using a co-dominant or log-additive model) we report the risk allele 
associated with an elevated risk. 
d We report multiplicative gene−environment interactions with a P for interaction <0.05 (Wald test).  
The environmental factor is highlighted in bold in case the interaction remained statistically significant after 
multiple testing adjustment using FDR and an FDR Q-value threshold of 0.20. The following pro- and 
antioxidant environmental factors were examined: toenail selenium levels, intake of β-carotene, lycopene, 
catechin, vitamin C, vitamin E, and heme iron, alcohol consumption, smoking status, antioxidant score, and 
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oxidative balance score. For SEPP1 SNPs, we only investigated potential interactions with selenium and not 
the other exposures. 
e The interaction between alcohol consumption and hOGG1 rs1052133 was significant for both stage III/IV 
and stage IV PCa risk (P <0.05). 
7.2 Interpretation of study findings 
7.2.1 Selenium and prostate cancer risk − Is low selenium status a risk factor for 
prostate cancer? 
Many prospective analyses, including our study, showed that selenium levels are 
inversely associated with PCa risk [1, 2]. The two clinical trials on selenium 
supplementation and PCa risk had mixed findings: the Nutritional Prevention of Cancer 
(NPC) trial showed, in a secondary analysis, that selenium supplementation reduced 
PCa risk [3], but the Selenium and Vitamin E Cancer Prevention Trial (SELECT), which 
was primarily designed to study PCa, found no beneficial effect of selenium on PCa risk 
[4]. 
The Nutritional Prevention of Cancer trial, Selenium and Vitamin E Cancer Prevention 
Trial, and Netherlands Cohort Study – Adequate selenium status for the prevention of 
prostate cancer? 
A major difference between the two clinical trials on selenium and PCa risk, the NPC 
trial and SELECT, is the baseline selenium level (Figure 7.1). The NPC trial, which 
showed a preventive effect of selenium supplementation on PCa risk, was conducted 
among subjects from the southeastern US [3]. This region was selected because it has 
relatively low soil selenium concentrations. A consequence of these lower selenium 
soil concentrations is that individuals from these regions have a lower selenium intake 
and status. The mean baseline plasma selenium level of men in the NPC trial was 115 
µg/L (standard deviation (SD) = 22 µg/L) [5]. SELECT, which showed no preventive 
effect of selenium supplementation on PCa risk, was conducted among men from 
various regions in the US, Canada, and Puerto Rico [6]. These individuals have 
relatively high selenium levels. The median baseline plasma selenium level in SELECT 
was 136 µg/L (interquartile range = 122–152). Because SELECT, unlike the NPC trial, 
was conducted among American men with higher selenium levels, average baseline 
selenium in SELECT may have already been sufficiently high, explaining why additional 
selenium supplementation had no effect on PCa risk. That baseline selenium in SELECT 
may have been adequate is supported by additional results from the NPC trial showing 
that the preventive effect of selenium on PCa risk was restricted to men in the lowest 
two tertiles of baseline selenium, i.e. lower than 123 µg/L plasma selenium (Figure 7.1) 
[5]. Most men in SELECT had a baseline selenium level higher than this cut point. 
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Figure 7.1 
Range of (baseline) selenium levels in the Netherlands Cohort Study (NLCS), Nutritional Prevention of Cancer 
(NPC) trial, and Selenium and Vitamin E Cancer Prevention Trial (SELECT), and approximate selenium levels 
required to optimize the plasma selenoproteins (GPX3 and SEPP1) 
The selenium range (black bar) in the NLCS is the average toenail selenium level of male subcohort members 
± standard deviation (Chapter 2 of this thesis). To convert toenail selenium levels to plasma selenium levels 
we used the simple conversion ratio described by Waters et al.: plasma selenium (μg/L) = toenail selenium 
(µg/g)/0.0067 [15]. The selenium range in the NPC trial is the average baseline plasma selenium level ± 
standard deviation [4]. The selenium range in SELECT is the interquartile range of baseline plasma selenium 
levels [5]. Plasma selenium levels required to optimize activity or concentration of the plasma 
selenoproteins GPX3 (± 92 μg/L) and SEPP1 (± 125 μg/L) are marked by dotted vertical lines [8-10]. In the 
NPC trial, selenium supplementation was associated with reduced PCa risk [2, 92], but when stratified by 
baseline plasma selenium the inverse association was only observed for men in the first two tertiles of 
baseline selenium (<123 μg/L) [4]. In SELECT, selenium supplementation was not associated with PCa risk 
overall, but when stratified by baseline toenail selenium men with the highest levels (>0.90 µg/g) had an 
increased risk of high-grade PCa from selenium supplementation [11]. 
Adequate selenium status is possibly related to plasma selenium levels needed to 
optimize activity or concentration of the plasma selenoproteins. GPX3 and SEPP1 are 
the plasma selenoproteins [7]. Both proteins serve as selenium nutritional markers and 
plasma GPX3 activity has been used to set dietary reference values for selenium [8]. 
The plasma selenium concentration needed to maximize GPX3 activity is 
approximately 92 μg/L [9, 10], which is expected to be sufficient to optimize activity of 
the other isoforms of GPX [10]. SEPP1 has a maximum concentration at a higher 
plasma selenium concentration of approximately 125 μg/L [10, 11]. Baseline plasma 
selenium levels in SELECT were clearly higher than the selenium concentrations 
needed to optimize these selenoproteins (Figure 7.1). This again suggests that most 
SELECT participants may already have had an adequate selenium intake at baseline. 
Furthermore, mean post-treatment plasma selenium in SELECT was 225 µg/L [12], 
Plasma/serum Se, µg/L 60 80 100 120 140
Toenail Se, µg/g 0.40 0.54 0.67 0.80 0.94
160
1.07
NPC trial
SELECT
NLCS
Optimized GPX3 Optimized SEPP1
Selenium reduces PCa risk
Selenium 
increases 
PCa risk
No effect
of 
selenium
No effect 
of 
selenium
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which is almost two times the concentration needed to optimize the plasma 
selenoproteins.  
Selenium concentrations in our study among men from the Netherlands were 
much lower than those in SELECT and the NPC trial (Figure 7.1). This is a result of the 
typically lower selenium soil concentrations in Europe [8, 13, 14]. In our study, we used 
toenail selenium concentrations for exposure monitoring. Toenail selenium status is an 
excellent selenium status biomarker because it reflects long-term selenium intake [2, 
15]. To convert toenail selenium levels to plasma selenium levels we used the simple 
conversion ratio described by Waters et al.: plasma selenium (μg/L) = toenail selenium 
(µg/g)/0.0067 [16]. In our study, the average toenail selenium level of 0.55 (SD = 0.13) 
approximates a plasma selenium level of 0.82 (SD = 0.19). Figure 7.1 shows that while 
the range of selenium in our study falls below the expected selenium level needed to 
optimize SEPP1, men with the highest selenium levels in our study are expected to 
have optimal GPX3 activity. Selenium status of most men in our study was also lower 
than 123 µg/L plasma selenium; men in the NPC trial with a baseline plasma selenium 
level higher than 123 µg/L had no effect of selenium supplementation on PCa risk [5]. 
Based on this prior scientific evidence, selenium levels in our study are clearly in the 
range were additional selenium intake is expected to be beneficial. 
That baseline selenium status may be important for the efficacy of selenium 
supplementation in PCa prevention is further highlighted by an additional investigation 
in SELECT [12]. Kristal et al. recently analyzed SELECT data stratified by baseline toenail 
selenium levels. The study showed that while selenium supplementation had no effect 
among men with low baseline selenium status (<60th percentile of toenail selenium) it 
increased risk of high-grade PCa (Gleason 7−10) among men with higher selenium 
status. Baseline toenail selenium levels in SELECT (mean = 0.89 µg/g) were much 
higher than toenail selenium levels in the Netherlands Cohort Study (mean = 0.55 
µg/g). The cut point for the highest selenium quintile in our study was 0.617 µg/g; only 
0.9% of PCa cases in SELECT had baseline selenium levels below this threshold. SELECT 
data demonstrate that high-dose selenium supplementation (200 mg 
selenomethionine daily) does not reduce PCa risk among men who are in the range of 
selenium status that is common in US men and may even increase risk among men at 
the highest range of selenium intake. These data do not rule out that selenium 
supplementation may benefit men who are not selenium-replete but have lower 
selenium levels comparable to those found in many European countries. A possible 
explanation for the unexpected finding in SELECT comes from a feeding trial of 
selenium supplementation in dogs, the only non-human animal model of spontaneous 
PCa [16]. This study showed a non-linear U-shaped dose–response relationship 
between selenium status and the extent of DNA damage in the aging prostate. That 
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dietary nutrients may have a U-shaped relationship with human disease/mortality has 
been reported for some nutrients other than selenium [17]. 
Blood and toenail selenium and novel selenium status biomarkers 
Much of our understanding of the complex dose−response relationship between 
selenium and PCa risk comes from studies using blood (plasma/serum) and toenail 
selenium concentrations as selenium status biomarkers. Blood and toenail selenium 
are valid selenium status biomarkers that respond over a wide range of selenium 
intake [8]. Both markers, however, may not accurately reflect selenium status in all 
situations. Levels of selenium in blood and toenails may depend on the type of 
selenium species in foods and supplements, subject characteristics, and dietary and 
other lifestyle exposures [8, 15]. Several novel selenium status biomarkers are being 
examined including selenoprotein gene expression levels in blood [8]. Future studies 
on selenium and PCa risk should consider using other selenium status biomarkers, in 
addition to blood and toenail selenium, which may provide important insights in the 
dose−response relationship between selenium status and PCa risk. 
7.2.2 Selenium and prostate cancer risk – A role for selenoprotein genes? 
The biological activities of selenium mainly depend on selenoproteins [14, 18]. Genetic 
variation in the genes encoding selenoproteins may influence PCa risk directly or by 
modifying the effect of selenium (gene−environment interaction). There have been a 
few prior studies on selenoprotein genes and PCa risk. The studies showed significant 
associations with PCa risk and survival for variants in a number of selenoprotein genes 
including SEPP1 [19, 20], GPX1 [21, 22], SEP15 [23], and TXNR1−2 [24]. The 
associations have only been reported in one or two studies and therefore require 
confirmation from other studies. Genome-wide association studies of PCa have not yet 
identified risk variants in selenoprotein genes [25]. 
In our study we investigated common genetic variation in SEPP1 and GPX1 (using 
tagging SNPs) in relation to toenail selenium levels and advanced PCa risk. We 
identified both genes as important candidates to modify PCa risk and the 
selenium−PCa association because (1) polymorphisms in both genes have previously 
been associated with PCa risk [14, 19, 22], and (2) both genes encode proteins with 
essential biological functions. SEPP1 is the main selenium transport protein in plasma 
and delivers selenium from the liver to other tissues [7]. GPX1 was the first 
selenoprotein identified and its strong antioxidant potential has been demonstrated in 
many mechanistic studies [26]. Furthermore, both genes come to expression in the 
prostate and there is some evidence that both genes are down-regulated in PCa [26-
28].  
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The results of our study showed that common genetic variants in SEPP1 (rs7579) 
and GPX1 (rs1800668, rs17650792) were associated with advanced PCa risk. We 
showed that the A allele of SEPP1 rs7579 was associated with decreased risk, which 
has not been reported before. The association was with stage IV PCa risk only. The 
association is supported by a study showing that men carrying this allele have higher 
serum concentrations of SEPP1 [29]. This polymorphism, its potential biological 
consequence, and the potential association it may have with PCa risk require further 
study. The GPX1 SNPs rs1800668 and rs17650792 are poorly studied genetic variants 
that have not been associated with PCa risk before. GPX1 rs17650792 is located near 
the GPX1 loci and is not correlated with other common genetic variants in GPX1. GPX1 
rs1800668 is located in the promoter of GPX1 and is in high linkage disequilibrium (LD) 
with GPX1 rs1050450 (r
2
 = 0.9). GPX1 rs1050450 resides in the coding region and this 
SNP may have functional consequences because it results in an amino acid substitution 
of proline with leucine [30, 31]. The observed association of GPX1 rs1800668 in our 
study may be due to its high correlation with GPX1 rs1050450, which may be the true 
functional polymorphism. This is supported by an earlier small case−control study, 
which showed that the variant allele of GPX1 rs1050450 was associated with reduced 
PCa risk [21]. In our study we observed no evidence that common SEPP1 and GPX1 
variants modify the inverse association between toenail selenium levels and advanced 
PCa risk (no gene–environment interaction). Three previous candidate gene studies 
investigated interactions between selenoprotein gene variants and selenium on PCa 
risk [19, 20, 23]. These studies were on overall PCa and one study showed a significant 
interaction for a SEPP1 variant [19], and another study for a GPX1 variant [20]. In our 
study, higher selenium levels were associated with reduced PCa risk independently of 
common genetic variation in SEPP1 and GPX1. These findings suggest that the 
beneficial effect of selenium on advanced PCa risk does not depend on common 
genetic variation in these two selenoprotein genes.  
In our study we focused on SEPP1 and GPX1, which according to us are the two 
most obvious candidate selenoprotein genes to play a role in PCa risk. The human 
selenoproteome is however encoded by 25 selenoprotein genes [18], and these other 
genes could also have an effect on PCa risk either directly or by modifying the effect of 
selenium. In our study, we did not investigate other selenoprotein genes because we 
could only genotype a small number of SNPs. We therefore believe that it is important 
for future gene association studies on PCa risk to further this research by investigating 
genetic variation in other selenoprotein genes (n = 23) and examine potential 
interactions with selenium. Particularly interesting candidate selenoprotein genes are 
genes encoding other isoforms of GPX (e.g., GPX2, GPX3, GPX4, and GPX6). Our study 
of GPX1 showed that variants in this gene were associated with advanced PCa risk 
suggesting that SNPs in other GPX genes may also influence PCa risk. All GPXs have 
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similar antioxidant functions that involve reduction of hydroperoxides [26]. Other 
selenoproteins that may play a role in PCa are the thioredoxin reductases (TXNR). 
These selenoproteins have a central role in the thioredoxin system, which is important 
for cellular redox control and signaling [32]. A laboratory study showed that loss of 
TRXN function because of oxidation and corresponding redox imbalance may play 
important roles in PCa progression [33]. Some other selenoproteins have biological 
functions that are however unlikely to play a role in cancer (e.g., iodothyronine 
deodinases) [18, 34]. While GPX and TXNR have well-known functions potentially 
involved in cancer, many other selenoproteins have poorly understood biological 
activities. These include selenoprotein H, I, K, M, O, S, T, V, and W and SEP15 [18, 34]. 
Further mechanistic research is needed to discover the precise functions of these 
proteins and identify functional variants in their genes. Furthermore, genes involved in 
selenoprotein synthesis may also play a role in PCa. The biosynthesis of selenoproteins 
involves the incorporation of selenocysteine in proteins and this process depends on 
multiple protein factors such as SECIS-binding protein 2 (SBP2) [18, 34]. Variation in 
genes encoding these proteins may influence the activity of selenoproteins and might 
therefore impact PCa risk. Only one previous study investigated genetic variation in 
this pathway in relation to PCa risk. This small case−control study investigated 
variation in SBP2 but found no association with PCa risk [24]. Finally, two recent 
genome-wide association studies investigated common genetic variation in relation to 
blood selenium levels [35, 36], and the studies identified a number of variants 
associated with selenium. Although it was not clear to what specific pathways the gene 
variants belong, they could potentially modify the effect of selenium on (advanced) 
PCa risk, which would be an interesting topic for a future study. 
7.2.3 Oxidative stress and prostate cancer risk – A role for pro- and antioxidant intake? 
Our study generally supports previous epidemiological research showing that intake of 
the major antioxidant nutrients vitamin C, vitamin E, β-carotene, and lycopene is 
unlikely to influence PCa risk. Our study did however show an association between 
higher flavonoid intake and reduced advanced PCa risk. Flavonoids are antioxidant 
polyphenols that include catechins and flavonols and a major dietary source of these 
components is black tea [37, 38]. Few other studies examined flavonoids in relation to 
PCa risk and these studies generally do not support an association [39]. Our study 
showed that both flavonoid intake and black tea consumption were associated with a 
reduced risk of advanced PCa but not overall or non-advanced PCa. In our study, 
flavonoid intake was estimated using a baseline FFQ and a potential limitation is that 
misclassification may have occurred. Future analyses would therefore benefit from 
biomarkers of flavonoid intake such as for example urinary markers [40]. Our 
observation that high black tea consumption reduces PCa risk is supported by a few 
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other studies [41, 42]. Most previous investigations of tea and PCa risk, however, 
exclusively studied overall PCa risk [43], and, additional studies are needed to confirm 
the inverse association with advanced PCa risk observed in our study.  
Based on the existing scientific evidence, an increased intake of well-known 
antioxidant nutrients such as vitamins and carotenoids is unlikely to reduce PCa risk in 
a generally healthy population. Antioxidant intake should therefore not be 
recommended for the prevention of PCa. Future observational studies on (modifiable) 
risk factors for PCa should focus on exposures other than antioxidant nutrients. It is 
however not ruled out that some antioxidants may influence PCa risk in specific 
subgroups such as for example men with a specific genetic background (e.g., oxidative 
stress-related SNPs; Chapter 7.2.4) or men who have very low baseline antioxidant 
levels (e.g., selenium; Chapter 7.2.1), and this should be investigated further. 
In addition to these antioxidants, there are some well-known pro-oxidant 
exposures including cigarette smoke, dietary iron, and alcohol [44-46]. These 
environmental exposures induce the formation of ROS and can thereby cause oxidative 
stress. Different observational studies investigated these pro-oxidants in relation to 
PCa risk, but they showed no convincing evidence of an association [47-52], which was 
confirmed by our study. Although prior research does not suggest that pro-oxidant 
intake increases PCa risk, exposure to pro-oxidants such as cigarette smoke and 
alcohol should be limited because they have many known adverse health effects other 
than the induction of PCa [44]. 
Pro- and antioxidant intake scores 
In our study we not only examined single pro- and antioxidant exposures but also 
investigated their combined effects using pro- and antioxidant scores. This may be 
important because these components act through the same pathway. We created two 
scores: (1) an antioxidant score (only antioxidants), and (2) an oxidative balance score 
(both pro- and antioxidants; scored in the opposite way). The scores included major 
well-known pro- and antioxidant exposures (e.g., antioxidant nutrients, smoking) and 
were based on previously described scores [45, 46, 53-57]. All score constituents were 
given an equal weight. In our study, both scores were not associated with PCa risk. Our 
findings are therefore not consistent with the hypothesis that a higher intake of many 
antioxidants or presumably beneficial balance between exogenous pro- and 
antioxidants protects against PCa. A few prior studies investigated comparable pro- 
and antioxidant scores in relation to PCa risk and these studies generally do not 
support an association [45, 58, 59]. We believe that our scores are important measures 
of pro- and antioxidant intake because they are literature-based and include well-
known pro- and antioxidants (e.g., antioxidant nutrients, smoking). These scores are 
therefore interesting tools to use in future epidemiological studies on oxidative stress 
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and disease risk or prognosis. A potential limitation of our scores is that they are 
unweighted; all score constituents were giving the same weight. The magnitude of the 
effects of the pro- and antioxidants may however differ. An alternative approach 
would be to weigh the individual pro- and antioxidants based on their measured 
activities. One such approach involves using the ferric-reducing antioxidant potential 
(FRAP) assay, which measures the reduction of ferric (Fe
3+
) to ferrous ion (Fe
2+
) and has 
been used to quantify total antioxidants in foods [60]. This approach however also has 
limitations. One important limitation is that FRAP measures the in vitro antioxidant 
potential, which may be very different from the in vivo situation. Once metabolized, 
pro- and antioxidants undergo many complex processes, which probably influence 
their activities. We therefore believe that a simple unweighted score as used in this 
thesis is the best available approach to study the combined effects of pro- and 
antioxidants in epidemiological studies. 
7.2.4 Oxidative stress and prostate cancer – A role for genetic variation? 
Oxidative stress possibly depends on genetic variation in oxidative stress-related 
genes. Different oxidative stress-related SNPs with potential functional consequences 
(e.g., altered enzyme activity) have been described [47, 61-66]. These genetic variants 
may influence PCa risk. Candidate gene association studies have investigated these 
gene variants in relation to PCa risk, and they showed significant associations with 
SNPs in different genes [22, 47, 61-69].  
In our study, we investigated 14 common genetic variants in major pro- and 
antioxidant genes that have reported functionality or have been associated with PCa 
risk before (Table 7.2). We investigated associations between these genetic variants 
and advanced PCa risk and found one SNP to be associated: CAT rs1001179. This SNP 
has previously been associated with PCa risk in a small case−control study [69]. The 
marginal association is biologically plausible because the minor allele of CAT 
rs1001179, which increased PCa risk in our study, has been associated with reduced 
catalase activity [61, 70]. Catalase is an antioxidant enzyme and a reduced catalase 
enzyme activity may result in deficient antioxidant protection against oxidative stress, 
which could potentially translate into a higher risk of developing PCa. We also showed 
marginal associations with two SNPs in the gene encoding the antioxidant enzyme 
GPX1. These results are discussed in Chapter 7.2.2. None of the other candidate SNPs 
were associated with advanced PCa risk. This is surprising because we selected 
candidate SNPs that have been associated with PCa risk in previous studies. The 
majority of these previous analyses however only examined overall PCa, and the fact 
that we specifically studied advanced PCa could explain the differences in outcome. 
Furthermore, many of the previously reported SNP associations were only reported in 
one or two studies, suggesting that they might have been due to chance. Our findings 
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suggest that specific antioxidant gene variants have a main effect on advanced PCa 
risk. Based on these findings, future gene−association studies are needed to extend 
this research and more comprehensively study underlying genetic variation. In 
particular, future studies would benefit from a tagging SNP approach (used in this 
thesis only for SEPP1 and GPX1) rather than a candidate SNP approach. By only 
studying specific candidate SNPs, we probably excluded other important genetic 
variants within the candidate genes that may affect PCa, for example those SNPs that 
have only been studied to a limited extent and therefore have unknown functional 
effects. Tagging SNPs allow capturing all common genetic variation in a gene by 
selecting a small number of SNPs within or near the gene of interest [71]. Given our 
findings, future studies may want to use tagging SNPs for CAT and GPX genes (i.e., 
GPX2−6). In our study we found that a CAT variant and two GPX1 variants were 
associated with advanced PCa risk. 
Genome-wide association studies (GWAS) of PCa have not identified risk variants 
in oxidative stress-related genes [25]. PCa GWAS do not confirm the observed marginal 
associations with variants in CAT and GPX1 (2 SNPs) in our study. There are a number 
of possible explanations for these mixed findings. First, while we specially studied 
advanced stage PCa, most PCa GWAS investigated overall PCa risk. Some recent GWAS 
have studied more aggressive PCa but these generally used a composite definition that 
included advanced stage, high grade, and PCa-specific death after additional follow-up 
[25, 72, 73]. The different definitions of advanced/aggressive PCa may explain the 
different outcomes. Second, GWAS require stringent P-values for statistical 
significance to prevent false positive results, which may cause associations with SNPs 
with weaker P-values to be missed [74]. Third, the candidate SNPs showing a marginal 
association in our study may have been poorly tagged in PCa GWAS (e.g., r
2
 <0.9). If 
GWAS SNPs do not strongly correlate with the actual causal variant, an association 
could be missed [75]. Fourth, GWAS findings might be biased due to an incorrect 
control selection approach [76], which may be a problem in many GWAS that use cases 
and control from different study bases. Fifth, GWAS generally do not consider 
environmental exposure. Genetic risk variants may interact with the environment and 
only have an effect on disease risk in subgroups exposed or unexposed to an 
environmental factor [77]. 
Gene−environment interactions 
Genetic variants and exposures may have a joint effect on disease risk via 
gene−environment interaction. The genetic variants may modify potential effects of 
environmental factors. There have been a few, mostly small, studies that investigated 
interactions between oxidative stress-related genetic variants and exposures (pro- and 
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antioxidants) in relation to PCa risk. These studies produced some statistically 
significant gene−environment interactions [47, 66, 78]. 
In this thesis we investigated interactions between the 14 oxidative stress-related 
gene variants and 11 pro- and antioxidant exposures in relation to advanced PCa risk. 
We tested 151 gene−environment interactions in relation to both stage III/IV and IV 
PCa risk. Because our analysis included a large number of tests (n = 302), we decided 
to adjust for multiple testing using the false discovery rate (FDR) approach [79-81]. We 
chose this approach because it is less conservative (than for example the Bonferroni 
method), which is important because our study is hypothesis-based and we, therefore, 
wanted to limit the probability of excluding true positives. We chose the FDR Q-value 
threshold of 0.20, which has been suggested for candidate gene studies [50, 51]. A 
lower threshold is often used in genome-wide association studies, which do not use 
prior information to select candidate genes [53]. Seven interactions were statistically 
significant after adjusting for multiple testing (FDR Q-value <0.20); for stage III/IV PCa 
these involved intake of β-carotene (GPX1 rs17650792, hOGG1 rs1052133) and heme 
iron (GPX1 rs1800668 and rs3448), and for stage IV PCa these involved intake of 
catechin (SOD2 rs4880) and heme iron (hOGG1 rs1052133, SOD1 rs10432782). These 
interactions were novel and showed no evidence of a dose−response relationship, i.e., 
an increase or decrease over exposure categories. We hypothesized that higher 
antioxidant intake is beneficial (higher pro-oxidant intake is damaging) but did not 
observe such a risk pattern for any of the 7 statistical interactions. Epidemiological 
studies have not investigated the reported statistically significant interactions in our 
study. There is also no mechanistic data that supports the gene−environment 
interactions. The positive findings in our study therefore require confirmation. When 
these findings are confirmed, additional mechanistic research is needed to discover 
the underlying biological mechanism explaining the interactions. A potential limitation 
of our approach is that we estimated exposure from a single baseline questionnaire 
(except for selenium where toenail selenium was used for exposure monitoring), which 
may have resulted in misclassification. Future studies should therefore consider other 
approaches to monitor environmental exposure. Based on the positive findings in our 
study, we believe that further research on this topic is needed. In our study we only 
investigated specific candidates and therefore potentially have excluded important 
genetic variants in the oxidative stress pathway. Future studies should examine other 
important SNPs that were not investigated in our study, which may result in novel 
findings. As discussed previously, future studies on this topic should consider using 
tagging SNPs for the genes investigated in our study to investigate all common 
variation within candidate genes. The seven significant interactions in our study 
involved the genes GPX1, hOGG1, SOD1, and SOD2. Given these findings, future 
studies should focus on the additional GPX and SOD genes (GPX2−6, SOD3). While GPX 
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and SOD are antioxidant enzymes, hOGG1 is involved in oxidative damage repair [66]. 
We only selected one SNP of this pathway, and future studies may want to investigate 
this more comprehensively and focus on other gene variants and genes of the 
oxidative damage repair pathway. 
7.3 Gene−environment interaction and exposure modification by genotype 
Studies of gene−environment interactions aim to describe how genetic and 
environmental factors jointly influence disease risk [82]. This type of analysis is 
important because it may provide biological insight and may help to identify 
genetically susceptible individuals [77]. Many of the examples of gene−environment 
interactions in the literature are examples of effect or exposure modification [83, 84]. 
The exposure modiﬁers are gene variants that act by inﬂuencing the function of a 
biological or metabolic pathway. The gene variants may inﬂuence response to a given 
level of exposure by changing how or how rapidly an exposure is absorbed, processed, 
or metabolized. A well-known example of exposure modiﬁcation by genotype involves 
bladder cancer [85]. The association between cigarette smoking and bladder cancer 
risk is modified by NAT2, with a higher relative risk from smoking for NAT2 slow 
acetylators compared to rapid or intermediate acetylators. This interaction is 
biologically plausible, since aromatic amines, which are thought to be the most 
important class of bladder carcinogens in tobacco smoke are detoxified by NAT2 [86]. 
Most gene−environment interaction studies to date are candidate gene studies, 
which include studies of single genes and exposures and more elaborate investigations 
of entire pathways including all of the genes and exposures thought to be involved in a 
particular mechanism [77]. Researchers are beginning to explore the possibility to 
study gene−environment interactions on a genome-wide scale [77]. Such an approach 
remains, however, challenging because of the large number of tests that needs to be 
conducted. The most effective way to apply and detect interactions in the context of 
GWAS is still unresolved [87]. To date, therefore, most comprehensive studies of 
gene−environment interactions are hypothesis-based analyses that focus on specific 
disease pathways.  
In our study, we tested for multiplicative gene−environment interactions. This 
type of interaction occurs when the combined effect of a gene and exposure is larger 
(or smaller) than the product of their individual effects [77, 88]. It is believed that it is 
most appropriate to test for multiplicative interaction when the goal of the study is to 
investigate disease etiology and when the variables under study affect the same 
disease mechanism, as was the case in our study [83]. The majority of 
gene−environment interaction studies test for multiplicative interaction [89]. The 
interactions are tested by entering a product term into a logistic regression model or 
Cox regression model (used in our study), which is implicitly exponential and thus 
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multiplicative [88, 89]. Another type of interaction is additive interaction, which occurs 
when the combined effect of gene and exposure is larger (or smaller) than the sum of 
their individual effects [77, 88]. We did not study interaction on an additive scale 
because there was no convincing a priori evidence that an additive model is more 
appropriate than a multiplicative model. Identifying the most appropriate model is a 
challenge in many gene−environment interaction studies and, therefore, future 
analyses may benefit from approaches that are less dependent on the choice of 
additive or multiplicative parameterizations [90]. Some researchers believe that it is 
best to report results of both additive and multiplicative interactions [91]. We decided 
to not do this in our study because this would result in a very large number of 
statistical tests (>600) and an associated higher risk of excluding true positives when 
adjusting for multiple testing. Furthermore, when environmental factors and genetic 
loci only have modest effects on disease risk, there will not be large differences 
between additive and multiplicative tests [84]. The factors in our study have relatively 
modest effects. We investigated single common SNPs, which typically show per-allele 
odds ratios ranging from 1.10–1.25 [25]. Most pro- and antioxidant exposures in our 
study also have reported main effects on PCa risk that are generally small [2, 50].  
7.4 Concluding remarks 
The thesis adds to an existing body of evidence that a low, suboptimal level of the 
antioxidant nutrient selenium increases the risk of advanced PCa. The preventive 
effect of selenium on men with low selenium status remains to be demonstrated in a 
large randomized controlled trial with PCa risk as the primary outcome of interest, 
which is required before selenium can be recommended for the prevention of PCa. 
Scientific evidence does not suggest that other major antioxidants nutrients (vitamins 
C and E, β-carotene, lycopene) or pro-oxidant environmental factors (smoking, alcohol, 
heme iron) influence PCa risk. Our study, however, found novel evidence that a higher 
intake of antioxidant flavonoids is associated with a decreased risk of advanced PCa, 
but this finding requires confirmation.  
Genetic variation in specific disease pathways may influence advanced PCa risk 
directly or via gene−environment interaction. Our study showed evidence that genetic 
variation in selenoprotein genes (main effects; no interaction with selenium levels) and 
oxidative stress-related genes (main effects; interactions with pro- and antioxidant 
intake) are involved in the development of advanced PCa, suggesting that these 
pathways play a role in the etiology of PCa. 
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7.5 Recommendations for future research 
Our study on selenium, selenoproteins, oxidative stress, and advanced PCa risk showed 
several statistically significant findings, which according to us invites further 
epidemiological research on this topic. We have a number of recommendations for 
these future analyses. 
First, future studies should not only investigate total PCa but also more advanced 
PCa. Many prior observational studies on PCa risk did not investigate more advanced 
PCa, and the few studies that did found some evidence that risk factors may differ for 
overall versus advanced PCa. Furthermore, this thesis found that while catechin intake 
was not associated with overall or non-advanced PCa risk, higher catechin intake was 
associated with a decreased advanced PCa risk. It is important to study the etiology of 
advanced PCa because this type of PCa has a poor prognosis and is therefore clinically 
relevant. 
Second, we showed an inverse association between selenium status and 
advanced PCa risk among men from the Netherlands who have relatively low selenium 
status. When the association is confirmed, it may be justified to perform a new 
prevention trial to determine whether (advanced) PCa risk can be reduced by 
increasing selenium status from suboptimal to optimal. Importantly, such a trial should 
focus on men from regions where selenium levels are low (e.g., European populations) 
and not on men who are selenium-replete (US men) because additional selenium is not 
expected to have a beneficial effect when baseline selenium is already adequate. 
Third, we showed that genetic variants in selenoprotein genes and genes related 
to oxidative stress influence advanced PCa risk. Our study utilizes a candidate gene 
approach and we may therefore have excluded important candidates. Future 
investigations are needed to further this research and study the role of additional 
potentially important candidate gene(s) (variants) in these pathways that were not 
examined in this thesis. These analyses would benefit from a tagging SNP approach, 
which allows capturing all common genetic variation in genes.  
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Summary 
Prostate cancer (PCa) is a common disease that is clinically heterogeneous. Only a 
subset of all PCa patients has advanced disease that is associated with a poor 
prognosis. Many other PCa patients have relatively slow-growing tumors that may 
never become clinically relevant when left untreated. The present thesis deals with 
PCa risk factors and specifically focuses on advanced PCa. Advanced PCa may have a 
different etiology compared to non-advanced PCa. Many previous studies on PCa risk 
factors only focused on overall PCa. In the present thesis, we investigated the role of 
selenium and the related oxidative stress pathway, which according to previous 
scientific research may play a role in (advanced) PCa development. Oxidative stress is a 
biological condition that results from an imbalance between reactive oxygen species 
and antioxidants in favor of the former. It has been hypothesized that oxidative stress 
is involved in aging and age-related diseases including PCa. Selenium is an essential 
micronutrient with antioxidant properties. The oxidative stress pathway includes many 
endogenous (genetic) and exogenous (environmental) pro- and antioxidants. 
The various analyses in this thesis were conducted within the large prospective 
Netherlands Cohort Study, which included 58,279 men at baseline in September 1986. 
Netherlands Cohort Study participants completed a baseline questionnaire on many 
potential cancer risk factors including pro- and antioxidant intake. Study participants 
also provided toenail clippings, which were used to measure selenium concentrations 
and to isolate DNA for genotyping. We used a candidate gene association approach 
and studied single nucleotide polymorphisms (SNPs), which are the most common type 
of genetic variation in humans. We studied SNPs in genes encoding major 
selenoproteins (through which selenium exerts its biological activities) and oxidative 
stress-related proteins (e.g., pro- and antioxidant enzymes). Cancer cases were 
prospectively identified by annual record linkage to cancer registries. For the research 
described in this thesis, a follow-up of 17.3 years was used (1986–2003). Clinical and 
pathological TNM (Tumor, Node, Metastasis) stage was used to classify PCa. Two 
definitions of advanced PCa were used, i.e.: stage III/IV PCa (T3−4, N+, or M1) and 
stage IV PCa (T4, N+, or M1). The Netherlands Cohort Study employs a case–cohort 
design, which involves using a subcohort to estimate the person-time experience. The 
advantage of this design is that it considerably reduces data collection, which is 
important because costly and time-consuming methods for exposure monitoring and 
genotyping were used in the thesis.  
In Chapter 2 of the thesis we investigated the association between toenail 
selenium levels and advanced PCa risk. Toenail selenium is a selenium status 
biomarker that reflects long-term selenium intake (compared to blood selenium), and 
our study was the first large study of toenail selenium and advanced PCa risk. In our 
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study population of men from the Netherlands with low to moderate selenium status, 
we found that toenail selenium levels were inversely associated with advanced PCa 
risk. An inverse association between selenium status and advanced PCa risk has been 
shown previously in several other prospective studies that used blood selenium for 
exposure monitoring. Future research on selenium and PCa risk should focus on men 
who have low, suboptimal selenium levels (e.g., European men). 
In Chapter 3 we studied the associations between common genetic variants in 
the major selenoprotein genes SEPP1 (5 tagging SNPs) and GPX1 (3 tagging SNPs) and 
advanced PCa risk and examined potential gene–environment interactions with toenail 
selenium levels. The study showed that SEPP1 and GPX1 gene variants influenced 
advanced PCa risk (marginal associations) but the variants did not modify the 
association with toenail selenium (no gene–environment interactions). The positive 
findings for SEPP1 and GPX1 in our study suggest that selenoprotein genes may play a 
role in the etiology of advanced PCa.  
In Chapters 4 and 5 of the thesis we studied pro- and antioxidant intake in 
relation to overall and advanced PCa risk. The study showed that most antioxidant 
nutrients (e.g., vitamins, carotenoids) and pro-oxidant exposures (e.g., smoking, 
alcohol), either separately or combined in a score, were not associated. This is 
supported by previous research on this topic. However, our study also showed that 
intake of antioxidant flavonoids and black tea (a major source of flavonoids) was 
associated with a reduced risk of advanced but not total PCa. Few other studies 
examined flavonoids in relation to (advanced) PCa risk and these studies generally do 
not support an association. Our findings therefore require confirmation from other 
studies. 
In Chapter 6 we investigated associations between SNPs in oxidative stress-
related genes and advanced PCa risk and examined potential interactions with pro- 
and antioxidant intake. The tested SNPs (n = 14) were candidate SNPs that have 
reported functionality or have been associated with PCa risk in previous studies. We 
found that a SNP in the antioxidant gene CAT (rs1001179) was associated with 
advanced PCa risk. The association has been reported in one previous study (for overall 
PCa) and is supported by functional data. Furthermore, we found seven novel gene–
environment interactions that retained significance after adjusting for multiple testing. 
The statistically significant multiplicative gene–environment interactions in our study 
suggest that the oxidative stress pathway is involved in the etiology of advanced PCa. 
We therefore think that additional epidemiological research on this topic is needed.  
In Chapter 7, the main study findings as well as the study limitations are 
discussed. Furthermore, recommendations for future studies are given. 
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Samenvatting 
Prostaatkanker is een veelvoorkomende ziekte waarvan uiteindelijk slechts een 
subgroep advanced (d.i., gevorderd stadium) zal worden. Advanced prostaatkanker is 
een type prostaatkanker dat geassocieerd is met een slechte prognose. Deze thesis 
gaat over risicofactoren voor advanced prostaatkanker. Wij onderzochten de mogelijke 
rol van selenium en de gerelateerde oxidatieve stress pathway. Oxidatieve stress is een 
biologische toestand die het gevolg is van een verstoorde balans tussen schadelijke 
reactieve zuurstofvormen (meer) en antioxidanten (minder). Oxidatieve stress is 
mogelijk betrokken bij veroudering en ouderdomsgerelateerde aandoeningen zoals 
prostaatkanker. Selenium is een essentieel micronutriënt en antioxidant. De oxidatieve 
stress pathway omvat verschillende endogene (genetische) en exogene 
(omgevingsfactoren) pro- en antioxidanten. 
De analyses beschreven in deze thesis zijn uitgevoerd in de prospectieve 
Nederlandse Cohortstudie (58279 mannen bij baseline in 1986). De studiedeelnemers 
hebben aan het begin van de studie een gedetailleerde vragenlijst (o.a. over dieet en 
andere leefstijlfactoren) ingevuld. Daarnaast hebben ongeveer 80% van de deelnemers 
een teennagelmonster aangeleverd. Dit biologisch materiaal werd in dit onderzoek 
gebruikt voor (1) het bestuderen van genetische variatie en (2) de bepaling van 
seleniumconcentraties. Wij onderzochten genetische variatie in belangrijke 
selenoproteïnegenen (de activiteit van selenium wordt uitgeoefend door deze genen) 
en genen van de oxidatieve stress pathway. Voor dit onderzoek werden de deelnemers 
van de studie 17.3 jaar gevolgd (1986–2003) voor het ontstaan van advanced (stadium 
III/IV of IV) prostaatkanker. De Nederlandse Cohortstudie maakt gebruik van het case–
cohort design. 
In Hoofdstuk 2 van de thesis onderzochten wij de associatie tussen 
teennagelseleniumwaarden en het risico op advanced prostaatkanker. Wij vonden dat 
een lage seleniumwaarde geassocieerd was met een sterk verlaagd risico op advanced 
prostaatkanker. 
In Hoofdstuk 3 bestudeerden wij de associaties tussen (tagging) genetische 
varianten in twee selenoproteïnegenen, d.i., SEPP1 en GPX1, en advanced 
prostaatkanker. Wij onderzochten tevens mogelijke gen–omgevingsinteracties met 
teennagelselenium. De studie toonde aan dat het risico op advanced prostaatkanker 
werd beïnvloed door de genetische varianten. De associatie tussen 
teennagelseleniumwaarden en advanced prostaatkanker werd echter niet 
gemodificeerd door de genetische varianten (d.i., geen gen–omgevingsinteractie). 
In Hoofdstuk 4 en 5 van de thesis bestudeerden wij de inname van pro- en 
antioxidanten in relatie tot totaal en advanced prostaatkanker. De meeste pro- en 
antioxidanten waren niet geassocieerd, d.i., als individuele factor of gecombineerd in 
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een score. Wij vonden wel dat een hogere inname van flavonoïden (een groep 
antioxidanten) geassocieerd was met een verlaagd risico op advanced prostaatkanker. 
Deze bevinding heeft nood aan bevestiging van andere studies. 
In Hoofdstuk 6 onderzochten wij de associaties tussen (kandidaat) genetische 
varianten in oxidatieve stress-gerelateerde genen en advanced prostaatkanker en 
bestudeerden potentiële interacties met inname van pro- en antioxidanten. Wij 
vonden dat een genetische variant in het catalase-gen (CAT) geassocieerd was met het 
risico op advanced prostaatkanker en identificeerden zeven statistisch significante 
gen–omgevingsinteracties. 
Hoofdstuk 7 omvat een wetenschappelijke discussie, mogelijke beperkingen van 
het onderzoek, en aanbevelingen voor toekomstig onderzoek. 
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Knowledge valorization refers to the utilization of scientific knowledge in practice. This 
section describes how the scientific findings in this thesis may have an impact on 
society or economy. The different study findings and their potential opportunities for 
knowledge valorization are discussed separately. 
Selenium 
Selenium is an essential micronutrient that may prevent the development of 
(advanced) prostate cancer (PCa). We conducted a prospective analysis to investigate 
the association between toenail selenium levels (a selenium status biomarker) and 
advanced PCa risk in a population of men from the Netherlands with low to moderate 
selenium status. Our study showed that higher toenail selenium levels were associated 
with a substantial decrease in risk of advanced PCa. The association is supported by 
other prospective studies that used blood selenium for exposure monitoring [1]. 
Previous prospective studies showed that the inverse association with selenium exists 
for both overall and advanced PCa, but is slightly more pronounced for advanced PCa. 
Despite the evidence from observational studies, selenium cannot be recommended 
for the prevention of PCa before such an effect has been demonstrated in a 
randomized controlled clinical trial with PCa risk as the primary outcome of interest. 
Designing and conducting such a trial could therefore be an important next step in this 
research. The trial should clearly focus on men from regions where selenium soil 
concentrations (and hence dietary selenium intake and status) are low (e.g., European 
men). 
If the anticancer effect of selenium has been demonstrated in a clinical trial and 
selenium can be used to reduce PCa risk, this would have important public health and 
economic consequences. PCa is the most common cancer in men. In the Netherlands 
in 2011, 11,428 men were diagnosed with PCa and 2,500 men died as a result of the 
disease [2]. According to data from the Netherlands National Institute for Public Health 
and the Environment the total costs for PCa in the Netherlands in 2011 were 254 
million Euro [3]. Furthermore, compared to other common cancers (e.g., breast, lung) 
PCa has no known modifiable risk factors [4, 5]. What is particularly important is that 
evidence supports that selenium may not only prevent total PCa but also more 
advanced PCa. This type of PCa is associated with a poor prognosis [6], and is therefore 
the most important type of PCa when it comes to prevention. While non-advanced 
prostate cancers have a 5-year survival rate of nearly 100%, this is considerably 
reduced for advanced PCa (45% for stage IV PCa) [7]. In addition, low selenium intake 
is common in many regions worldwide [8], suggesting that there is a very large target 
population that would potentially benefit from additional selenium intake. In addition, 
while our study focused on PCa, low-selenium is believed to be a potential risk factor 
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for many other chronic diseases (e.g., other cancers, cardiovascular disease) [8]. This 
further highlights the social and economic relevance of counteracting the problem of 
low selenium intake. 
A number of strategies can potentially be used to increase selenium intake. These 
strategies should focus on men from regions with low selenium soil concentrations 
who therefore have a low selenium intake and status (e.g., European men). The 
simplest and safest strategy to increase selenium intake is to consume more foods that 
are rich sources of selenium (e.g., specific types of fish, meat, nuts). Identifying those 
foods can be done by dietitians who then could develop specialized dietary 
recommendations and guidelines for low-selenium men. Further research is needed to 
design and optimize such dietary interventions. Selenium intake can also be increased 
by using selenium supplements. However, it is important to note that high-dose 
supplementation may cause harm in some situations. This has also been demonstrated 
for selenium [9]. It will therefore be important that the industry develops low-dose 
selenium supplements that are safe to use by men from low-selenium regions and that 
efficiently increase selenium status from suboptimal to optimal but not greater than 
optimal. Another possibility to indirectly increase selenium intake is to increase 
selenium soil concentrations in low selenium regions. Higher soil selenium levels will 
result in higher selenium levels in the foods grown on these soils. This has been 
successfully done in Finland in the 1980s by using selenium enriched fertilizers [10]. 
Therefore, policy makers in other countries with low selenium soil concentrations may 
consider using a similar strategy to increase selenium soil levels and the associated 
selenium intake in these regions. 
Selenoprotein gene variants 
Selenium exerts its biological activity through selenoproteins. The human 
selenoproteome is encoded by 25 known selenoprotein genes [11]. We conducted a 
gene association study to investigate how genetic variants in selenoprotein genes 
influence advanced PCa risk directly or by modifying the effect of selenium. Genetic 
variants in these genes may influence the activity of selenoproteins. We focused on 
two selenoprotein genes, i.e., SEPP1 (involved in selenium transport) and GPX1 
(involved in antioxidant protection). Our study showed marginal associations for 
variants in both genes, suggesting a role for these genes, and the pathways they are 
involved in, in advanced PCa development. Genetic variation in the genes did, 
however, not modify the association with toenail selenium levels (no gene–
environment interaction). There have been few other studies that investigated 
selenoprotein genes in relation to selenium status and advanced PCa risk. 
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Gene–environment interaction research is primarily focused on understanding 
the etiology of a disease. Knowledge valorization is no primary aim of this research and 
there are therefore no immediate opportunities to use the findings from these studies 
to create value. One potential long-term opportunity to use gene–environment 
interactions in practice is to identify genetically susceptible individuals. For example, 
genetic variation in selenoprotein genes may influence the activity of selenoproteins 
and therefore how selenium intake affects advanced PCa risk. Specific selenoprotein 
gene variants may cause certain individuals to become more susceptible to low 
selenium status. If that is the case, selenoprotein gene variants can be used to identify 
those genetically susceptible individuals that are expected to benefit (more) from 
additional selenium intake. The gene variants could then potentially be used as a tool 
by medical specialists, for example to make recommendations or dietary guidelines on 
selenium supplementation. The gene variants may also be used by researchers 
planning a future trial on selenium supplementation and PCa risk. Although our study 
indicated that the effect of selenium on advanced PCa risk was independent of SEPP1 
and GPX1 common variation, other selenoprotein genes may still play a role. 
Therefore, further gene association studies are needed to investigate the potential role 
of other selenoprotein genes (n = 23) not investigated in our study. It is important to 
note that identifying genetically susceptible individuals using gene–environment 
interactions will require more research on a number of questions related to feasibility, 
costs, ethical issues, etcetera; before such findings can be used in practice. 
Flavonoids 
Our prospective study showed that a higher intake of antioxidant flavonoids (catechins 
and flavonols) was associated with a reduced risk of advanced PCa, but not overall or 
non-advanced PCa. Few other studies examined flavonoids in relation to (advanced) 
PCa risk and these studies generally do not support an association. Our findings 
therefore require confirmation from other studies. We also investigated the 
associations of (intake of) other antioxidant nutrients (e.g., vitamins, carotenoids) and 
pro-oxidant exposures (i.e., smoking). Our study showed no evidence of an association 
of these exposures, which was confirmed by previous epidemiological research [12, 
13].  
It is important that we do research on dietary and other lifestyle factors in 
relation to PCa risk. PCa is a common cancer with no established modifiable risk factors 
(unlike other common cancers) [4, 5]. According to the most recent data 
approximately 1 in 7 US men will develop PCa during his lifetime. A potential 
preventive effect of flavonoid intake could therefore help reduce the enormous social 
and economic impact of PCa (also see section on selenium and PCa risk, page 148–
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149). What is particularly interesting is that the inverse association with flavonoid 
intake in our study was specifically for advanced PCa. This type of PCa is clinically 
relevant because it has a poor prognosis [6], unlike non-advanced PCa. Advanced PCa 
is therefore the most important type of PCa when it comes to prevention.  
Our finding that flavonoids may reduce the risk of advanced PCa requires 
confirmation from other studies, and flavonoids cannot be recommended for the 
prevention of PCa before such an effect has been demonstrated in a large clinical trial. 
Assuming our findings were to be confirmed; how can flavonoids be used to reduce 
the incidence of advanced PCa? One simple strategy would be to recommend men 
with a low flavonoid intake to consume more foods that are rich sources of flavonoids. 
These foods include tea, apples, onions, chocolate, legumes, cabbages, and leafy 
vegetables. Dietitians could develop dietary guidelines/recommendations for these 
men to increase their flavonoid intake/status to an optimal level. Further research is 
needed to determine how this can exactly be achieved. Additional research is also 
needed to determine the subgroups that are most likely to benefit from such an 
intervention. Furthermore, our finding that flavonoids were inversely associated with 
advanced but not overall or non-advanced PCa risk suggests that flavonoids may 
reduce the progression of PCa. If that is the case, flavonoids can potentially be used for 
the secondary prevention of PCa, i.e., preventing PCa progression (e.g., prostate-
specific antigen (PSA) progression, biochemical recurrence, metastasis, lethal PCa) in 
patients who already have PCa. This has to be investigated in future prognostic studies. 
Oxidative stress-related genetic variants  
The potential effects of pro- and antioxidant nutrients/exposures on advanced PCa risk 
may depend on genetic variation (i.e., gene–environment interactions), specifically 
variation in genes encoding oxidative stress-related proteins. We prospectively 
investigated this in the Netherlands Cohort Study and we discovered a number of 
gene–environment interactions, seven of which retained significance after multiple 
testing adjustment. We also studied associations between the oxidative stress-related 
gene variants and advanced PCa risk and found that a catalase SNP was marginally 
associated. The positive findings in our study highlight that the oxidative stress 
pathway may play a role in advanced PCa development and this should motivate other 
researchers to continue to investigate the oxidative stress–PCa hypothesis. Future 
research should include gene–association studies (that focus on additional candidate 
SNPs) but also mechanistic studies. Mechanistic studies are important to discover how 
oxidative stress-related genes and exposures may have a joint effect. For example, 
most gene–environment interactions found in our study were difficult to interpret 
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because they did not involve a dose−response pattern that involved a distinct decrease 
or increase in risk over exposure categories, as we hypothesized.  
Findings from gene–environment interaction research can potentially be used to 
identify genetically susceptible individuals, for example subjects that are expected to 
benefit more or less from a specific (e.g., dietary) intervention. This could lead to 
genetic tests or tools that can help clinical decision making. However, there are several 
open questions that remain to be answered before findings from gene–environment 
interaction research can be brought to practice (i.e., costs, ethical issues, feasibility, 
false positives). Currently, there are a number of ongoing projects aimed at 
incorporating genotyping data to make dietary and other types of recommendations 
[14]. Whether these initiatives are successful remains to be demonstrated in the 
future. Our type of analysis forms the basis for these initiatives. 
In conclusion, this text shows examples of how the scientific findings from this thesis 
can potentially be used in practice to create value. Further research is needed to 
carefully explore the opportunities for knowledge valorization. 
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